Eli Lilly and Company(NYSE:LLY) 
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix...
Website: http://www.lilly.com
Founded: 1876
Full Time Employees: 35,065
CEO: David A. Ricks
Sector: Healthcare
Industry: Drug Manufacturers-General
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
- Weight-Loss and Diabetes Franchise Driving Growth: Demand for Lilly’s incretin-based medicines (notably Mounjaro and Zepbound) remains a key engine for revenue and volume growth, expanding the company’s metabolic disease leadership.
- Manufacturing Capacity Expansion Is Central to the Story: Lilly continues to invest heavily in expanding and securing supply chains for injectable therapies, aiming to alleviate constraints, support new indications, and sustain long-term scale.
- Pipeline Depth Supports Multi-Year Optionality: Beyond current blockbusters, Lilly’s R&D pipeline spans cardiometabolic, oncology, immunology, and neuroscience programs, providing multiple potential catalysts and diversification over time.
- Pricing and Reimbursement Scrutiny Remains a Key Risk: As demand grows for obesity and diabetes therapies, policy and payer pressure (rebates, formulary access, and government pricing initiatives) could influence net pricing and profitability.
- Valuation Tied to Execution and Competitive Dynamics: With high market expectations, share performance is sensitive to manufacturing ramp progress, trial readouts, competitive obesity market developments, and any shifts in demand or safety perceptions.
Bull Thesis:
- Dominance in the GLP-1 Market (Zepbound/Mounjaro): Eli Lilly's GLP-1 agonists, Mounjaro (diabetes) and Zepbound (obesity), are experiencing unprecedented demand due to their high efficacy and safety profiles. The market for weight loss and diabetes management is massive and growing, with LLY positioned as a leader, driving significant revenue growth and market share, with ongoing investments to expand manufacturing capacity.
- Promising Alzheimer's Drug (Donanemab) on the Horizon: Donanemab, LLY's investigational Alzheimer's treatment, has shown positive clinical trial results and is awaiting regulatory approval. If approved, it could tap into a vast unmet medical need, offering a significant new revenue stream and strengthening LLY's neuroscience portfolio, despite potential reimbursement complexities.
- Robust and Diversified Pipeline Beyond GLP-1s: Beyond its current blockbusters and late-stage candidates, Eli Lilly boasts a deep and diversified pipeline across multiple therapeutic areas including oncology, immunology, and other metabolic disorders. This ensures sustained long-term growth potential and reduces over-reliance on a single drug or therapeutic class, providing future revenue drivers.
- Strong Pricing Power and Expanding Profit Margins: Eli Lilly's portfolio of highly innovative and effective drugs, particularly in areas with high unmet needs, allows for strong pricing power. This, combined with efficient operations and the high-margin nature of biologics, contributes to expanding profit margins and robust free cash flow generation, supporting further R&D and shareholder returns.
Bear Thesis:
- Intense Competition in the GLP-1 Market: While Eli Lilly currently holds a strong position, the GLP-1 market is becoming increasingly competitive with Novo Nordisk as a formidable rival and numerous other companies developing next-generation obesity and diabetes treatments. This could lead to pricing pressure, market share erosion, and limit long-term growth potential as new entrants emerge.
- Elevated Valuation and High Expectations: Eli Lilly's stock has experienced a significant run-up, reflecting extremely high expectations for its GLP-1 franchise and pipeline. Any slowdown in growth, pipeline setbacks, increased competition, or unexpected regulatory hurdles could lead to a substantial correction in its valuation, as much of the future growth is already priced in.
- Supply Chain and Manufacturing Challenges: The unprecedented demand for Mounjaro and Zepbound has led to persistent supply constraints. While LLY is investing heavily in manufacturing capacity, continued shortages could limit sales growth, frustrate healthcare providers and patients, and potentially allow competitors to gain ground during periods of limited availability.
- Regulatory and Reimbursement Hurdles for Donanemab: Donanemab's approval for Alzheimer's disease is not guaranteed, and even if approved, its market penetration could be limited by strict reimbursement policies (especially from government payers like Medicare) and ongoing safety monitoring (e.g., ARIA). This could temper its revenue potential compared to initial high expectations.
Main Competitors:
- Novo Nordisk A/S ($NVO) (Ozempic, Wegovy), Novo Nordisk is Eli Lilly's most direct and fierce competitor, particularly in the lucrative diabetes and obesity markets. They compete head-to-head with their GLP-1 receptor agonist drugs (Ozempic for diabetes, Wegovy for obesity) against Lilly's Mounjaro and Zepbound. Competition revolves around efficacy, safety, convenience, market access, and pipeline development for next-generation weight loss and diabetes treatments.
- Pfizer Inc. ($PFE) (Ibrance, Xeljanz), Pfizer is a broad pharmaceutical competitor, challenging Eli Lilly across multiple therapeutic areas including oncology, immunology, and neuroscience. They compete through their extensive R&D pipeline, established drug portfolios, and global market presence. Competition involves developing novel therapies, expanding indications for existing drugs, and vying for market share in areas like breast cancer (Ibrance vs. Verzenio) and inflammatory diseases.
- Johnson & Johnson (Janssen Pharmaceutical Companies) ($JNJ) (Stelara, Darzalex), Johnson & Johnson's pharmaceutical division, Janssen, competes with Eli Lilly in immunology, oncology, and neuroscience. They develop and market a wide range of innovative medicines, challenging Lilly through their strong pipeline, established blockbuster drugs (e.g., Stelara in immunology, Darzalex in multiple myeloma), and global commercial capabilities. Competition focuses on clinical differentiation, patient outcomes, and market access strategies.
- Merck & Co., Inc. ($MRK) (Keytruda), Merck is a significant competitor, especially in the oncology space, where its blockbuster immunotherapy Keytruda dominates. They compete with Eli Lilly's oncology portfolio (e.g., Verzenio, Cyramza) by developing new cancer treatments, expanding indications for Keytruda across various tumor types, and investing heavily in immuno-oncology research. Competition also extends to vaccines and other therapeutic areas.
- AstraZeneca PLC ($AZN) (Tagrisso, Farxiga), AstraZeneca competes with Eli Lilly in key therapeutic areas such as oncology, cardiovascular, renal & metabolism (CVRM), and immunology. They challenge Lilly through their strong oncology pipeline (e.g., Tagrisso for lung cancer), diabetes/CVRM drugs (e.g., Farxiga), and ongoing R&D efforts to discover and commercialize innovative medicines. Competition involves clinical superiority, market penetration, and strategic partnerships.
Moat:
Eli Lilly operates in a highly competitive global pharmaceutical market. Its primary moat stems from its robust R&D pipeline, successful commercialization of innovative drugs, and strong patent protection for its blockbuster therapies. Competition is intense and multifaceted, driven by other large pharmaceutical companies vying for market share in key therapeutic areas like diabetes, obesity, oncology, and immunology. Competitors challenge Lilly through developing novel mechanisms of action, demonstrating superior efficacy and safety profiles in clinical trials, securing favorable market access and pricing, and expanding indications for existing drugs. The industry's competitive landscape necessitates continuous innovation and strategic investment in research and development to maintain and grow market leadership.
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-09-30 | 2011-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue | 19,799,000,000 | 19,292,000,000 | 17,600,800,000 | 15,557,700,000 | 12,728,500,000 | 13,532,800,000 | 11,439,100,000 | 11,302,800,000 | 8,768,000,000 | 9,353,400,000 | 9,498,600,000 | 8,312,100,000 | 6,960,000,000 | 7,301,800,000 | 6,941,600,000 | 6,488,000,000 | 7,810,000,000 | 7,999,900,000 | 6,772,800,000 | 6,740,100,000 | 6,805,600,000 | 7,440,000,000 | 5,740,600,000 | 5,499,400,000 | 5,859,800,000 | 6,114,000,000 | 5,476,600,000 | 5,636,700,000 | 5,092,200,000 | 6,438,600,000 | 6,061,900,000 | 6,355,200,000 | 5,700,000,000 | 6,160,700,000 | 5,658,000,000 | 5,824,300,000 | 5,228,300,000 | 5,760,500,000 | 5,191,700,000 | 5,404,800,000 | 4,865,100,000 | 5,375,600,000 | 4,959,700,000 | 4,978,700,000 | 4,644,700,000 | 5,121,300,000 | 4,875,600,000 | 4,935,600,000 | 4,683,100,000 | 5,808,800,000 | 5,772,600,000 | 5,929,700,000 | 5,602,000,000 | 5,957,400,000 | 5,443,300,000 | 5,600,700,000 | 5,602,000,000 | 6,147,900,000 | 6,252,800,000 |
yoy | 55.55% | 42.56% | 53.87% | 37.64% | 45.17% | 44.68% | 20.43% | 35.98% | 25.98% | 28.10% | 36.84% | 28.11% | -10.88% | -8.73% | 2.49% | -3.74% | 14.76% | 7.53% | 17.98% | 22.56% | 16.14% | 21.69% | 4.82% | -2.44% | 15.07% | -5.04% | -9.66% | -11.31% | -10.66% | 4.51% | 7.14% | 9.12% | 9.02% | 6.95% | 8.98% | 7.76% | 7.47% | 7.16% | 4.68% | 8.56% | 4.75% | 4.97% | 1.72% | 0.87% | -0.82% | -11.84% | -15.54% | -16.76% | -16.40% | -2.49% | 6.05% | 5.87% | 0.00% | -3.10% | -12.95% | ||||
qoq | 2.63% | 9.61% | 13.13% | 22.23% | -5.94% | 18.30% | 1.21% | 28.91% | -6.26% | -1.53% | 14.27% | 19.43% | -4.68% | 5.19% | 6.99% | -16.93% | -2.37% | 18.12% | 0.49% | -0.96% | -8.53% | 29.60% | 4.39% | -6.15% | -4.16% | 11.64% | -2.84% | 10.69% | -20.91% | 6.21% | -4.62% | 11.49% | -7.48% | 8.88% | -2.86% | 11.40% | -9.24% | 10.96% | -3.94% | 11.09% | -9.50% | 8.39% | -0.38% | 7.19% | -9.31% | 5.04% | -1.22% | 5.39% | -19.38% | 0.63% | -2.65% | 5.85% | -5.97% | 9.44% | -2.81% | -0.02% | -8.88% | -1.68% | |
costs, expenses, and other: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of sales | 3,577,000,000 | 3,371,700,000 | 3,008,300,000 | 2,447,800,000 | 2,224,200,000 | 2,403,800,000 | 2,170,800,000 | 2,170,200,000 | 1,673,500,000 | 1,788,000,000 | 1,860,100,000 | 1,807,400,000 | 1,626,700,000 | 1,548,100,000 | 1,579,100,000 | 1,430,500,000 | 2,072,100,000 | 2,050,200,000 | 1,430,800,000 | 1,953,200,000 | 1,878,600,000 | 1,719,800,000 | 1,326,400,000 | 1,222,000,000 | 1,215,100,000 | 1,282,600,000 | 1,175,000,000 | 1,124,900,000 | 1,138,700,000 | 1,593,700,000 | 1,562,300,000 | 1,702,700,000 | 1,571,300,000 | 1,624,800,000 | 1,566,100,000 | 1,551,600,000 | 1,327,700,000 | 1,466,000,000 | 1,400,900,000 | 1,465,000,000 | 1,323,000,000 | 1,389,200,000 | 1,236,900,000 | 1,218,400,000 | 1,192,700,000 | 1,253,100,000 | 1,267,000,000 | 1,189,700,000 | 1,222,700,000 | 1,386,500,000 | 1,198,100,000 | 1,165,200,000 | 1,158,300,000 | 1,248,300,000 | 1,203,600,000 | 1,146,700,000 | 1,197,900,000 | 1,338,100,000 | 1,228,000,000 |
research and development | 3,510,000,000 | 3,801,500,000 | 3,465,700,000 | 3,336,100,000 | 2,733,700,000 | 3,022,500,000 | 2,734,100,000 | 2,711,200,000 | 2,522,800,000 | 2,562,700,000 | 2,409,100,000 | 2,356,500,000 | 1,985,100,000 | 1,995,900,000 | 1,802,900,000 | 1,781,900,000 | 1,610,100,000 | 1,959,400,000 | 1,708,900,000 | 1,672,800,000 | 1,684,800,000 | 1,838,000,000 | 1,465,400,000 | 1,390,200,000 | 1,392,100,000 | 1,581,400,000 | 1,380,900,000 | 1,402,200,000 | 1,230,500,000 | 1,453,800,000 | 1,343,300,000 | 1,333,100,000 | 1,176,900,000 | 1,473,200,000 | 1,319,400,000 | 1,250,900,000 | 1,238,300,000 | 1,450,600,000 | 1,236,400,000 | 1,335,900,000 | 1,221,000,000 | 1,444,200,000 | 1,143,400,000 | 1,169,500,000 | 1,039,300,000 | 1,185,700,000 | 1,243,200,000 | 1,195,400,000 | 1,109,300,000 | 1,475,400,000 | 1,377,400,000 | 1,330,400,000 | 1,348,100,000 | 1,463,100,000 | 1,342,800,000 | 1,320,700,000 | 1,151,500,000 | 1,280,900,000 | 1,260,600,000 |
marketing, selling, and administrative | 2,934,000,000 | 3,131,400,000 | 2,740,700,000 | 2,753,000,000 | 2,468,800,000 | 2,424,500,000 | 2,099,800,000 | 2,117,300,000 | 1,952,200,000 | 1,924,600,000 | 1,803,900,000 | 1,925,400,000 | 1,749,200,000 | 1,643,200,000 | 1,614,200,000 | 1,625,100,000 | 1,557,900,000 | 1,592,000,000 | 1,577,900,000 | 1,685,700,000 | 1,576,000,000 | 1,553,900,000 | 1,569,100,000 | 1,448,600,000 | 1,549,600,000 | 1,698,100,000 | 1,412,300,000 | 1,586,300,000 | 1,517,100,000 | 1,861,500,000 | 1,616,600,000 | 1,653,700,000 | 1,500,000,000 | 1,780,500,000 | 1,555,500,000 | 1,707,400,000 | 1,544,700,000 | 1,790,100,000 | 1,565,400,000 | 1,622,600,000 | 1,473,900,000 | 1,798,400,000 | 1,575,700,000 | 1,635,400,000 | 1,523,500,000 | 1,799,900,000 | 1,672,100,000 | 1,663,900,000 | 1,484,900,000 | 1,953,600,000 | 1,652,400,000 | 1,867,600,000 | 1,652,000,000 | 1,977,500,000 | 1,757,400,000 | 1,931,100,000 | 1,847,500,000 | 1,917,800,000 | 2,043,000,000 |
acquired in-process research and development | 584,000,000 | 528,800,000 | 655,700,000 | 153,800,000 | 1,571,700,000 | 189,200,000 | 2,826,400,000 | 154,300,000 | 110,500,000 | 622,600,000 | 2,975,100,000 | 97,100,000 | 105,000,000 | 376,600,000 | 174,000,000 | 25,000,000 | 299,300,000 | 366,300,000 | 241,800,000 | 52,300,000 | 77,700,000 | 25,000,000 | 136,900,000 | 329,400,000 | 30,000,000 | 1,624,500,000 | 50,000,000 | 205,000,000 | 857,600,000 | 199,000,000 | 80,000,000 | 256,000,000 | 105,200,000 | 95,000,000 | |||||||||||||||||||||||||
asset impairment, restructuring, and other special charges | 279,000,000 | 84,100,000 | 364,900,000 | 35,000,000 | 344,000,000 | 81,600,000 | 435,000,000 | 38,100,000 | 206,500,000 | 104,500,000 | 211,600,000 | -30,100,000 | 101,400,000 | 59,900,000 | 151,700,000 | 423,900,000 | 246,000,000 | 83,300,000 | 74,400,000 | 78,300,000 | 1,003,200,000 | 406,500,000 | 50,000,000 | 213,900,000 | 147,600,000 | 45,500,000 | 58,000,000 | 131,400,000 | 144,900,000 | 42,400,000 | 72,400,000 | 108,000,000 | 401,000,000 | 36,300,000 | 31,400,000 | ||||||||||||||||||||||||
other–net, expense | 65,000,000 | 115,675,000 | 133,100,000 | 90,600,000 | 239,000,000 | 27,125,000 | -62,000,000 | 197,600,000 | -27,100,000 | 6,075,000 | 23,200,000 | 36,800,000 | -35,700,000 | 145,225,000 | 111,000,000 | 119,200,000 | 350,700,000 | 31,075,000 | 635,900,000 | -190,500,000 | -321,100,000 | -173,725,000 | -158,900,000 | -446,900,000 | -89,100,000 | -7,175,000 | 24,900,000 | 32,400,000 | -86,000,000 | -22,525,000 | 15,400,000 | -38,000,000 | -67,500,000 | 675,000 | 13,900,000 | 3,900,000 | -15,100,000 | 25,150,000 | -27,200,000 | -21,200,000 | 149,000,000 | ||||||||||||||||||
costs, expenses, and other: - sum | 10,949,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before income taxes | 8,850,000,000 | 8,266,200,000 | 7,232,400,000 | 6,776,400,000 | 3,456,100,000 | 5,038,700,000 | 1,588,400,000 | 3,517,200,000 | 2,536,100,000 | 2,508,800,000 | 427,200,000 | 2,088,900,000 | 1,529,700,000 | 2,096,400,000 | 1,565,500,000 | 1,090,900,000 | 2,053,600,000 | 1,839,900,000 | 1,245,300,000 | 1,593,900,000 | 1,476,400,000 | 2,469,100,000 | 1,437,200,000 | 1,643,700,000 | 1,679,900,000 | 1,663,100,000 | 1,405,800,000 | 1,465,900,000 | 731,100,000 | 938,900,000 | 1,411,000,000 | 4,800,000 | 1,441,000,000 | 284,100,000 | 591,600,000 | 1,260,500,000 | 61,200,000 | 892,000,000 | 970,700,000 | 944,500,000 | 566,800,000 | 444,600,000 | 1,047,800,000 | 679,700,000 | 617,900,000 | 513,600,000 | 655,500,000 | 940,400,000 | 890,800,000 | 909,900,000 | 1,513,400,000 | 1,514,900,000 | 1,951,100,000 | 1,012,500,000 | 1,874,700,000 | 1,185,700,000 | 1,335,300,000 | 1,502,500,000 | 1,531,300,000 |
income taxes | 1,454,000,000 | 1,628,500,000 | 1,649,900,000 | 1,115,900,000 | 696,800,000 | 628,900,000 | 618,100,000 | 550,200,000 | 293,200,000 | 319,100,000 | 484,600,000 | 325,700,000 | 184,800,000 | 158,700,000 | 113,800,000 | 138,400,000 | 150,700,000 | 113,800,000 | 135,200,000 | 203,700,000 | 121,100,000 | 352,300,000 | 228,800,000 | 231,700,000 | 223,400,000 | 167,400,000 | 151,900,000 | 138,700,000 | 170,000,000 | -186,100,000 | 261,500,000 | 264,700,000 | 223,600,000 | 1,941,000,000 | 36,000,000 | 252,500,000 | 172,000,000 | 120,200,000 | 192,700,000 | 196,800,000 | 126,700,000 | -33,800,000 | 248,100,000 | 78,900,000 | 88,400,000 | 85,100,000 | 154,900,000 | 206,900,000 | 162,900,000 | 182,400,000 | 310,300,000 | 308,700,000 | 403,100,000 | 185,200,000 | 548,100,000 | 262,100,000 | 324,200,000 | 266,200,000 | 334,000,000 |
net income | 7,396,000,000 | 6,637,700,000 | 5,582,500,000 | 5,660,500,000 | 2,759,300,000 | 4,409,800,000 | 970,300,000 | 2,967,000,000 | 2,242,900,000 | 2,189,700,000 | -57,400,000 | 1,763,200,000 | 1,344,900,000 | 1,937,700,000 | 1,451,700,000 | 952,500,000 | 1,902,900,000 | 1,726,100,000 | 1,110,100,000 | 1,390,200,000 | 1,355,300,000 | 2,116,800,000 | 1,208,400,000 | 1,412,000,000 | 1,456,500,000 | 1,495,700,000 | 1,253,900,000 | 1,327,200,000 | 4,241,600,000 | 1,125,000,000 | 1,149,500,000 | -259,900,000 | 1,217,400,000 | -1,656,900,000 | 555,600,000 | 1,008,000,000 | -110,800,000 | 771,800,000 | 778,000,000 | 747,700,000 | 440,100,000 | 478,400,000 | 799,700,000 | 600,800,000 | 529,500,000 | 428,500,000 | 500,600,000 | 733,500,000 | 727,900,000 | 727,500,000 | 1,203,100,000 | 1,206,200,000 | 1,548,000,000 | 827,300,000 | 1,326,600,000 | 923,600,000 | 1,011,100,000 | 1,236,300,000 | 1,197,300,000 |
yoy | 168.04% | 50.52% | 475.34% | 90.78% | 23.02% | 101.39% | -1790.42% | 68.27% | 66.77% | 13.01% | -103.95% | 85.11% | -29.32% | 12.26% | 30.77% | -31.48% | 40.40% | -18.46% | -8.13% | -1.54% | -6.95% | 41.53% | -3.63% | 6.39% | -65.66% | 32.95% | 9.08% | -610.66% | 248.41% | -167.90% | 106.89% | -125.78% | -1198.74% | -314.68% | -28.59% | 34.81% | -125.18% | 61.33% | -2.71% | 24.45% | -16.88% | 11.65% | 59.75% | -18.09% | -27.26% | -41.10% | -58.39% | -39.19% | -52.98% | -12.06% | -9.31% | 30.60% | 53.10% | -33.08% | 10.80% | ||||
qoq | 11.42% | 18.90% | -1.38% | 105.14% | -37.43% | 354.48% | -67.30% | 32.28% | 2.43% | -3914.81% | -103.26% | 31.10% | -30.59% | 33.48% | 52.41% | -49.94% | 10.24% | 55.49% | -20.15% | 2.58% | -35.97% | 75.17% | -14.42% | -3.06% | -2.62% | 19.28% | -5.52% | -68.71% | 277.03% | -2.13% | -542.29% | -121.35% | -173.47% | -398.22% | -44.88% | -1009.75% | -114.36% | -0.80% | 4.05% | 69.89% | -8.01% | -40.18% | 33.11% | 13.47% | 23.57% | -14.40% | -31.75% | 0.77% | 0.05% | -39.53% | -0.26% | -22.08% | 87.11% | -37.64% | 43.63% | -8.65% | -18.22% | 3.26% | |
net income margin % | 37.36% | 34.41% | 31.72% | 36.38% | 21.68% | 32.59% | 8.48% | 26.25% | 25.58% | 23.41% | -0.60% | 21.21% | 19.32% | 26.54% | 20.91% | 14.68% | 24.36% | 21.58% | 16.39% | 20.63% | 19.91% | 28.45% | 21.05% | 25.68% | 24.86% | 24.46% | 22.90% | 23.55% | 83.30% | 17.47% | 18.96% | -4.09% | 21.36% | -26.89% | 9.82% | 17.31% | -2.12% | 13.40% | 14.99% | 13.83% | 9.05% | 8.90% | 16.12% | 12.07% | 11.40% | 8.37% | 10.27% | 14.86% | 15.54% | 12.52% | 20.84% | 20.34% | 27.63% | 13.89% | 24.37% | 16.49% | 18.05% | 20.11% | 19.15% |
earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 8.27 | 7.4 | 6.22 | 6.3 | 3.07 | 4.9 | 1.08 | 3.29 | 2.49 | 2.43 | -0.06 | 1.96 | 1.49 | 2.15 | 1.61 | 1.06 | 2.11 | 1.063 | 1.22 | 1.53 | 1.49 | 1.1 | 1.13 | -0.25 | 1.16 | -1.57 | 0.53 | 0.96 | -0.1 | 0.73 | 0.74 | 0.71 | 0.42 | 0.45 | 0.75 | ||||||||||||||||||||||||
diluted | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 | 4.88 | 1.07 | 3.28 | 2.48 | 2.42 | -0.06 | 1.95 | 1.49 | 2.14 | 1.61 | 1.05 | 2.1 | 1.058 | 1.22 | 1.53 | 1.49 | 1.1 | 1.12 | -0.25 | 1.16 | -1.56 | 0.53 | 0.95 | -0.1 | 0.73 | 0.73 | 0.71 | 0.41 | 0.45 | 0.75 | ||||||||||||||||||||||||
shares used in calculation of earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 894.5 | -0.5 | 896.9 | 897.9 | 898.7 | 899,704.1 | 901 | 900.9 | 900.8 | 899,280.8 | 899.8 | 899.7 | 901 | 900,834.2 | 900.7 | 900.3 | 903.7 | 906,055.3 | 906.7 | 907.3 | 908.8 | 906,726.5 | 907.2 | 907.2 | 908.2 | 930,120.8 | 913.9 | 920.8 | 979.9 | 1,026,687.8 | 1,020.4 | 1,030.2 | 1,048 | 1,050,968.2 | 1,053.4 | 1,055 | 1,056.3 | 1,057,265.6 | 1,057.7 | 1,057.7 | 1,059.9 | 1,060,850.6 | 1,061.4 | ||||||||||||||||
diluted | 895.9 | -0.4 | 898.8 | 899.8 | 900.6 | 903,154.6 | 905 | 904.2 | 903.8 | 902,380.9 | 899.8 | 902.7 | 903.3 | 903,714.5 | 903.8 | 902.9 | 906.4 | 910,769.3 | 910.8 | 910.4 | 912.4 | 911,593.1 | 911.4 | 910.9 | 911.7 | 934,741.6 | 918.5 | 924.6 | 984 | 1,032,629.2 | 1,026.3 | 1,030.2 | 1,049.8 | 1,050,966 | 1,056 | 1,057.1 | 1,056.3 | 1,060,763.9 | 1,060.8 | 1,060.1 | 1,063.1 | 1,064,654 | 1,065.2 | ||||||||||||||||
acquired in-process research and development and development milestones | 240,100,000 | 62,400,000 | 440,400,000 | 165,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations | 2,116,800,000 | 1,208,400,000 | 1,412,000,000 | 1,456,500,000 | 1,495,700,000 | 1,253,900,000 | 1,327,200,000 | 561,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
net income from discontinued operations | 3,680,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings from continuing operations - basic | 2.33 | 1.33 | 1.56 | 1.6 | 1.63 | 1.37 | 1.44 | 0.57 | |||||||||||||||||||||||||||||||||||||||||||||||||||
earnings from discontinued operations - basic | 0.03 | 3.76 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share - basic | 2.33 | 1.33 | 1.56 | 1.6 | 1.66 | 1.37 | 1.44 | 4.33 | |||||||||||||||||||||||||||||||||||||||||||||||||||
earnings from continuing operations - diluted | 2.32 | 1.33 | 1.55 | 1.6 | 1.63 | 1.37 | 1.44 | 0.57 | |||||||||||||||||||||||||||||||||||||||||||||||||||
earnings from discontinued operations - diluted | 0.02 | 3.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share - diluted | 2.32 | 1.33 | 1.55 | 1.6 | 1.65 | 1.37 | 1.44 | 4.31 | |||||||||||||||||||||||||||||||||||||||||||||||||||
dividends paid per share | 0.563 | 0.563 | 0.39 | 0.52 | 0.52 | 0.52 | 0.383 | 0.51 | 0.51 | 0.51 | 0.375 | 0.5 | 0.5 | 0.5 | 0.368 | 0.49 | 0.49 | 0.49 | 0.368 | 0.49 | 0.49 | 0.49 | 0.368 | 0.49 | 0.49 | 0.49 | 0.49 | 0.49 | |||||||||||||||||||||||||||||||
other–net, income | -13,975,000 | -86,500,000 | 123,300,000 | -92,700,000 | -50,825,000 | -93,500,000 | -53,800,000 | -56,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares outstanding, including incremental shares | 1,061.7 | 1,064.2 | 1,069,932 | 1,069.6 | 1,071.7 | 1,072.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per share | 0.57 | 0.5 | 0.4 | 0.47 | 0.68 | 0.68 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares outstanding, including incremental shares and stock options | 1,065.6 | 1,067 | 1,074,286 | 1,074.4 | 1,076.4 | 1,075.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per share | 0.56 | 0.5 | 0.41 | 0.47 | 0.68 | 0.68 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
asset impairments, restructuring, and other special charges | 21,300,000 | 63,500,000 | 21,700,000 | 204,000,000 | 53,300,000 | 23,800,000 | 25,200,000 | 132,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
other – net, income | -127,450,000 | 31,300,000 | -11,900,000 | -529,200,000 | -181,500,000 | -788,500,000 | 83,400,000 | 57,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share – basic | 0.913 | 1.11 | 1.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share – diluted | 0.91 | 1.11 | 1.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share – basic and diluted | 1.42 | 0.73 | 1.18 | 0.83 | 0.91 | 1.11 | 1.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
other – net, expense | 16,500,000 | 46,000,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-09-30 | 2012-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 5,282,000,000 | 7,268,000,000 | 9,791,900,000 | 3,375,900,000 | 3,093,300,000 | 3,268,400,000 | 3,369,000,000 | 3,223,600,000 | 2,460,200,000 | 2,818,600,000 | 2,380,800,000 | 2,694,500,000 | 3,545,900,000 | 2,067,000,000 | 2,617,400,000 | 2,622,900,000 | 2,459,200,000 | 3,818,500,000 | 3,788,200,000 | 3,220,000,000 | 3,002,400,000 | 3,657,100,000 | 3,595,300,000 | 2,365,100,000 | 1,699,000,000 | 2,337,500,000 | 1,563,800,000 | 2,290,200,000 | 2,036,400,000 | 7,998,200,000 | 8,960,000,000 | 6,817,300,000 | 3,084,300,000 | 6,536,200,000 | 3,724,300,000 | 3,069,900,000 | 2,616,900,000 | 4,582,100,000 | 3,489,000,000 | 3,238,000,000 | 2,307,600,000 | 3,666,400,000 | 3,238,800,000 | 3,315,500,000 | 3,064,800,000 | 3,871,600,000 | 3,165,800,000 | 3,765,700,000 | 3,888,000,000 | 4,368,900,000 | 3,786,500,000 | 3,936,600,000 | 5,319,200,000 | 4,345,800,000 |
accounts receivable | 18,429,000,000 | 17,760,000,000 | 16,107,400,000 | 14,170,400,000 | 12,036,600,000 | 11,005,700,000 | 10,294,800,000 | 11,027,900,000 | 7,885,600,000 | 9,090,500,000 | 8,167,100,000 | 7,516,100,000 | 7,526,200,000 | 6,896,000,000 | 6,715,300,000 | 6,364,500,000 | 6,322,500,000 | 6,672,800,000 | 5,914,300,000 | 5,829,400,000 | 5,592,800,000 | 5,875,300,000 | 4,886,700,000 | 4,828,900,000 | 5,106,100,000 | 4,547,300,000 | 4,441,700,000 | 4,612,500,000 | 4,200,500,000 | 5,246,500,000 | 4,859,400,000 | 4,823,000,000 | 4,495,100,000 | 4,546,300,000 | 4,401,300,000 | 4,349,900,000 | 4,017,200,000 | 4,029,400,000 | 3,848,500,000 | 3,947,900,000 | 3,622,600,000 | 3,513,000,000 | 3,401,900,000 | 3,348,800,000 | 3,142,500,000 | 3,234,600,000 | 3,053,500,000 | 3,187,900,000 | 3,002,900,000 | 3,445,000,000 | 3,579,100,000 | 3,439,700,000 | 3,268,200,000 | 3,181,700,000 |
other receivables | 2,748,000,000 | 2,395,000,000 | 3,349,800,000 | 3,035,200,000 | 1,966,600,000 | 2,269,700,000 | 1,756,900,000 | 2,051,100,000 | 2,127,900,000 | 2,245,700,000 | 2,196,700,000 | 1,655,300,000 | 1,495,900,000 | 1,662,900,000 | 1,609,500,000 | 1,307,900,000 | 1,483,200,000 | 1,454,400,000 | 1,110,700,000 | 1,073,400,000 | 1,065,800,000 | 1,053,700,000 | 958,100,000 | 946,700,000 | 1,246,400,000 | 994,200,000 | 1,096,200,000 | 977,500,000 | 977,500,000 | 958,400,000 | 793,200,000 | 756,100,000 | 775,600,000 | 715,900,000 | 613,200,000 | 606,200,000 | 596,700,000 | 736,900,000 | 672,900,000 | 545,200,000 | 564,800,000 | 558,600,000 | 665,800,000 | 747,800,000 | 683,200,000 | 566,700,000 | 581,100,000 | 566,200,000 | 743,200,000 | 550,400,000 | 634,900,000 | 589,400,000 | 527,300,000 | 590,000,000 |
inventories | 14,529,000,000 | 13,744,000,000 | 12,180,400,000 | 11,013,800,000 | 9,311,000,000 | 7,589,200,000 | 7,459,800,000 | 6,481,500,000 | 6,101,800,000 | 5,772,800,000 | 4,901,400,000 | 4,798,700,000 | 4,544,800,000 | 4,309,700,000 | 3,831,100,000 | 3,899,400,000 | 3,893,000,000 | 3,886,000,000 | 3,907,400,000 | 3,824,900,000 | 3,660,800,000 | 3,980,300,000 | 3,555,400,000 | 3,313,900,000 | 3,102,400,000 | 3,190,700,000 | 3,101,300,000 | 3,181,100,000 | 3,055,200,000 | 4,111,800,000 | 4,118,000,000 | 4,155,500,000 | 4,631,300,000 | 4,458,300,000 | 4,406,900,000 | 4,346,000,000 | 4,035,100,000 | 3,561,900,000 | 3,881,200,000 | 3,759,900,000 | 3,740,200,000 | 3,445,800,000 | 3,417,700,000 | 3,288,400,000 | 2,980,200,000 | 2,740,000,000 | 2,844,500,000 | 3,190,300,000 | 2,969,000,000 | 2,974,100,000 | 2,725,400,000 | 2,576,700,000 | 2,553,400,000 | 2,320,800,000 |
prepaid expenses | 13,633,000,000 | 14,315,000,000 | 20,248,700,000 | 18,019,800,000 | 14,653,900,000 | 8,340,500,000 | 8,250,600,000 | 7,137,600,000 | 6,348,600,000 | 5,540,800,000 | ||||||||||||||||||||||||||||||||||||||||||||
other current assets | 214,000,000 | 147,000,000 | 271,500,000 | 68,800,000 | 72,400,000 | 111,400,000 | 134,600,000 | 142,200,000 | 138,600,000 | 149,500,000 | ||||||||||||||||||||||||||||||||||||||||||||
total current assets | 54,835,000,000 | 55,629,000,000 | 62,071,300,000 | 49,854,000,000 | 41,261,200,000 | 32,739,700,000 | 31,415,100,000 | 30,204,300,000 | 25,188,800,000 | 25,727,000,000 | 23,007,000,000 | 21,331,600,000 | 20,811,400,000 | 18,034,500,000 | 17,639,900,000 | 17,115,200,000 | 16,964,700,000 | 18,452,400,000 | 17,808,300,000 | 17,295,500,000 | 16,604,500,000 | 17,462,100,000 | 16,239,900,000 | 14,581,900,000 | 13,994,200,000 | 13,709,600,000 | 12,661,800,000 | 13,454,500,000 | 12,597,500,000 | 20,549,600,000 | 20,685,900,000 | 18,332,700,000 | 16,261,500,000 | 19,202,100,000 | 17,428,400,000 | 15,746,500,000 | 12,976,200,000 | 15,101,400,000 | 13,385,900,000 | 12,977,300,000 | 11,714,600,000 | 12,573,600,000 | 12,567,000,000 | 12,346,000,000 | 11,742,700,000 | 12,179,800,000 | 12,110,500,000 | 13,156,700,000 | 13,039,300,000 | 13,202,200,000 | 12,639,300,000 | 12,326,100,000 | 14,038,900,000 | 12,307,300,000 |
noncurrent assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
investments | 3,116,000,000 | 2,802,000,000 | 2,808,300,000 | 3,207,400,000 | 3,222,700,000 | 3,215,900,000 | 3,200,200,000 | 2,877,600,000 | 3,086,900,000 | 3,052,200,000 | 2,691,700,000 | 2,745,100,000 | 2,750,400,000 | 2,901,800,000 | 2,574,600,000 | 2,587,200,000 | 2,727,300,000 | 3,212,600,000 | 3,350,500,000 | 3,474,900,000 | 3,232,400,000 | 2,966,800,000 | 2,476,200,000 | 2,406,400,000 | 2,148,700,000 | 1,962,400,000 | 1,825,300,000 | 1,852,700,000 | 2,111,400,000 | 2,020,700,000 | 2,005,800,000 | 2,059,600,000 | 5,375,100,000 | 5,678,800,000 | 6,148,700,000 | 5,723,300,000 | 5,297,700,000 | 5,207,500,000 | 5,027,000,000 | 4,449,200,000 | 3,764,300,000 | 3,646,600,000 | 4,102,000,000 | 4,099,100,000 | 4,576,500,000 | 4,568,900,000 | 7,405,500,000 | 6,649,700,000 | 7,204,800,000 | 7,220,200,000 | 6,561,400,000 | 5,636,200,000 | 5,224,300,000 | 4,547,600,000 |
goodwill | 6,130,000,000 | 5,898,000,000 | 5,898,000,000 | 5,770,500,000 | 5,770,500,000 | 5,770,300,000 | 5,768,400,000 | 5,768,200,000 | 4,939,600,000 | 4,939,700,000 | 4,085,200,000 | 4,078,900,000 | 4,073,100,000 | 4,073,000,000 | 3,891,600,000 | 3,891,800,000 | 3,892,000,000 | 3,892,000,000 | 3,884,100,000 | 3,884,200,000 | 3,877,400,000 | 3,766,500,000 | 3,726,400,000 | 3,723,200,000 | 3,779,100,000 | 3,679,400,000 | 3,772,500,000 | 3,820,100,000 | 3,855,900,000 | 4,347,500,000 | 4,358,400,000 | 4,333,100,000 | 4,412,400,000 | 4,370,100,000 | 4,365,600,000 | 4,290,800,000 | 4,188,000,000 | 3,972,700,000 | 4,007,700,000 | 4,026,500,000 | 4,045,100,000 | 4,039,900,000 | 4,054,900,000 | 4,024,700,000 | 3,946,900,000 | 1,758,100,000 | ||||||||
other intangibles | 7,374,000,000 | 6,521,000,000 | 6,446,700,000 | 5,908,300,000 | 6,012,200,000 | 6,166,300,000 | 6,537,300,000 | 6,636,100,000 | 6,762,200,000 | 6,906,600,000 | 6,781,700,000 | 6,903,500,000 | 7,087,100,000 | 7,206,600,000 | 7,124,100,000 | 7,497,700,000 | 7,482,400,000 | 7,691,900,000 | 7,887,700,000 | 7,985,400,000 | 8,087,800,000 | 7,450,000,000 | 7,588,600,000 | 7,712,500,000 | 7,766,700,000 | 6,618,000,000 | 6,689,300,000 | 6,586,600,000 | 6,641,500,000 | 3,521,000,000 | 3,619,400,000 | 3,772,100,000 | 3,920,000,000 | 4,029,200,000 | 4,271,600,000 | 4,542,600,000 | 4,716,700,000 | 4,357,900,000 | 4,638,500,000 | 4,806,300,000 | 4,889,800,000 | 5,034,800,000 | 4,615,900,000 | 4,842,900,000 | 4,947,700,000 | 2,884,200,000 | ||||||||
deferred tax assets | 11,350,000,000 | 9,959,000,000 | 8,962,700,000 | 9,427,400,000 | 8,573,200,000 | 8,000,600,000 | 7,392,300,000 | 6,655,300,000 | 5,633,900,000 | 5,477,300,000 | 4,574,800,000 | 3,805,900,000 | 3,406,700,000 | 2,792,900,000 | 2,384,300,000 | 2,371,900,000 | 2,464,900,000 | 2,489,300,000 | 2,625,600,000 | 2,674,900,000 | 2,649,900,000 | 2,830,400,000 | 2,555,300,000 | 2,481,800,000 | 2,471,600,000 | 2,572,600,000 | 2,412,800,000 | 2,507,400,000 | 2,511,000,000 | 2,657,700,000 | 3,132,300,000 | 3,314,400,000 | 3,681,600,000 | |||||||||||||||||||||
property and equipment | 26,540,000,000 | 24,675,000,000 | 22,316,000,000 | 20,529,700,000 | 18,474,100,000 | 17,102,400,000 | 16,171,800,000 | 14,829,400,000 | 13,624,000,000 | 12,913,600,000 | 11,863,200,000 | 11,277,400,000 | 10,546,200,000 | 10,144,000,000 | 9,311,300,000 | 9,128,200,000 | 9,102,700,000 | 8,985,100,000 | 8,920,400,000 | 8,855,500,000 | 8,630,100,000 | 8,681,900,000 | 8,281,100,000 | 7,981,100,000 | 7,897,900,000 | 7,872,900,000 | 7,801,500,000 | 7,847,500,000 | 7,780,000,000 | 8,919,500,000 | 8,814,100,000 | 8,770,800,000 | 8,958,200,000 | 8,826,500,000 | 8,598,500,000 | 8,582,800,000 | 8,425,500,000 | 8,252,600,000 | 8,251,900,000 | 8,066,100,000 | 8,033,100,000 | 8,053,500,000 | 8,075,300,000 | 8,022,600,000 | 7,950,700,000 | 7,963,900,000 | 8,043,300,000 | 8,100,900,000 | 7,970,700,000 | 7,767,400,000 | 7,636,700,000 | 7,623,400,000 | 7,638,900,000 | 7,619,900,000 |
other noncurrent assets | 7,231,000,000 | 6,992,000,000 | 6,432,400,000 | 6,225,300,000 | 6,074,900,000 | 5,719,700,000 | 5,121,800,000 | 4,903,900,000 | 4,708,100,000 | 4,989,900,000 | 4,911,900,000 | 4,671,600,000 | 4,488,100,000 | 4,337,000,000 | 4,535,700,000 | 4,471,600,000 | 4,285,300,000 | 4,082,700,000 | 3,710,400,000 | 3,638,600,000 | 3,756,200,000 | 3,475,400,000 | 3,078,500,000 | 3,080,100,000 | 3,044,600,000 | 2,339,100,000 | ||||||||||||||||||||||||||||
total assets | 116,576,000,000 | 112,476,000,000 | 114,935,400,000 | 100,922,600,000 | 89,388,800,000 | 78,714,900,000 | 75,606,900,000 | 71,874,800,000 | 63,943,500,000 | 64,006,300,000 | 57,915,500,000 | 54,814,000,000 | 53,163,000,000 | 49,489,800,000 | 47,461,500,000 | 47,063,600,000 | 46,919,300,000 | 48,806,000,000 | 48,187,000,000 | 47,809,000,000 | 46,838,300,000 | 46,633,100,000 | 43,946,000,000 | 41,967,000,000 | 41,102,800,000 | 39,286,100,000 | 37,893,100,000 | 38,666,400,000 | 38,006,800,000 | 43,908,400,000 | 44,625,100,000 | 42,359,200,000 | 44,355,600,000 | 44,981,000,000 | 43,010,400,000 | 40,946,500,000 | 37,624,300,000 | 38,805,900,000 | 37,590,300,000 | 36,475,300,000 | 34,691,800,000 | 35,568,900,000 | 36,304,700,000 | 36,036,600,000 | 35,653,900,000 | 37,178,200,000 | 34,648,800,000 | 35,018,400,000 | 34,756,900,000 | 33,965,600,000 | 33,226,000,000 | 32,300,100,000 | 34,321,000,000 | 31,812,600,000 |
liabilities and equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term borrowings and current maturities of long-term debt | 4,000,000,000 | 1,635,000,000 | 1,633,000,000 | 5,723,700,000 | 4,016,400,000 | 5,117,100,000 | 2,074,300,000 | 5,161,600,000 | 1,651,500,000 | 6,904,500,000 | 2,244,700,000 | 661,600,000 | 3,100,000 | 1,501,100,000 | 1,744,600,000 | 2,121,800,000 | 1,355,900,000 | 1,538,300,000 | 1,563,000,000 | 1,778,500,000 | 4,900,000 | 8,700,000 | 587,500,000 | 1,263,800,000 | 3,248,000,000 | 1,499,300,000 | 1,563,100,000 | 2,068,600,000 | 2,354,900,000 | 1,131,200,000 | 1,002,200,000 | 3,049,100,000 | 2,304,200,000 | 3,706,600,000 | 3,538,100,000 | 2,444,200,000 | 2,609,300,000 | 1,937,400,000 | 641,500,000 | 645,800,000 | 648,300,000 | 6,100,000 | 9,300,000 | 10,800,000 | 805,400,000 | 2,688,700,000 | 313,000,000 | 10,300,000 | 9,100,000 | 1,019,100,000 | 1,023,200,000 | 1,028,000,000 | 9,100,000 | 9,100,000 |
accounts payable | 5,029,000,000 | 5,379,000,000 | 4,262,200,000 | 4,075,700,000 | 3,442,000,000 | 3,228,600,000 | 2,886,500,000 | 2,924,800,000 | 2,473,700,000 | 2,598,800,000 | 2,435,100,000 | 2,474,200,000 | 2,015,900,000 | 1,930,600,000 | 1,683,200,000 | 1,659,300,000 | 1,433,300,000 | 1,670,600,000 | 1,566,800,000 | 1,597,800,000 | 1,639,600,000 | 1,606,700,000 | 1,430,100,000 | 1,247,200,000 | 1,207,700,000 | 1,405,300,000 | 1,114,900,000 | 1,198,900,000 | 1,168,100,000 | 1,412,300,000 | 1,281,200,000 | 1,316,900,000 | 1,267,400,000 | 1,410,700,000 | 1,200,100,000 | 1,257,200,000 | 1,220,100,000 | 1,349,300,000 | 1,161,200,000 | 1,207,800,000 | 1,151,600,000 | 1,338,200,000 | 1,179,300,000 | 1,153,000,000 | 1,179,600,000 | 1,128,100,000 | 1,023,300,000 | 1,124,600,000 | 1,149,900,000 | 1,247,400,000 | 1,141,000,000 | 974,400,000 | 1,328,700,000 | 1,201,600,000 |
employee compensation | 1,359,000,000 | 2,375,000,000 | 1,965,700,000 | 1,303,000,000 | 1,113,900,000 | 2,093,900,000 | 1,703,300,000 | 1,168,300,000 | 844,200,000 | 1,650,400,000 | 1,233,200,000 | 867,700,000 | 739,700,000 | 1,059,800,000 | 984,100,000 | 835,800,000 | 693,100,000 | 958,100,000 | 836,600,000 | 755,500,000 | 649,900,000 | 997,200,000 | 795,600,000 | 673,600,000 | 565,800,000 | 915,500,000 | 704,500,000 | 588,200,000 | 511,700,000 | 1,054,500,000 | 858,500,000 | 710,500,000 | 588,100,000 | 997,900,000 | 821,100,000 | 668,400,000 | 566,500,000 | 896,900,000 | 738,500,000 | 622,500,000 | 548,700,000 | 967,000,000 | 829,600,000 | 672,600,000 | 518,700,000 | 759,000,000 | 701,100,000 | 633,400,000 | 554,800,000 | 805,200,000 | 671,300,000 | 543,700,000 | 772,700,000 | 602,900,000 |
sales rebates and discounts | 17,547,000,000 | 17,382,000,000 | 17,620,200,000 | 14,537,400,000 | 11,550,300,000 | 11,539,300,000 | 12,429,700,000 | 12,446,800,000 | 9,429,600,000 | 11,689,000,000 | 11,522,300,000 | 10,389,900,000 | 9,529,500,000 | 8,784,100,000 | 8,568,400,000 | 7,991,400,000 | 6,768,700,000 | 6,845,800,000 | 7,185,600,000 | 7,035,800,000 | 5,821,400,000 | 5,853,000,000 | 5,745,200,000 | 5,282,200,000 | 4,703,900,000 | 4,933,600,000 | 5,277,000,000 | 4,993,700,000 | 4,455,700,000 | 5,021,900,000 | 5,129,400,000 | 4,745,100,000 | 4,348,000,000 | 4,465,100,000 | 4,332,700,000 | 4,029,100,000 | 3,697,500,000 | 3,914,900,000 | 3,547,500,000 | 3,098,800,000 | 2,601,100,000 | 2,560,100,000 | 2,541,800,000 | 2,328,100,000 | 2,025,700,000 | 2,068,800,000 | 1,970,600,000 | 1,875,700,000 | 1,724,200,000 | 2,014,100,000 | 1,797,500,000 | 1,693,800,000 | 1,695,600,000 | 1,628,600,000 |
other current liabilities | 8,699,000,000 | 8,457,000,000 | 5,215,400,000 | 5,076,900,000 | 3,769,800,000 | 5,051,400,000 | 5,580,300,000 | 4,249,200,000 | 4,199,100,000 | 3,281,300,000 | 2,585,400,000 | 2,271,600,000 | 2,193,500,000 | 2,370,300,000 | 1,986,900,000 | 2,003,500,000 | 2,536,700,000 | 3,027,500,000 | 2,326,500,000 | 2,624,900,000 | 2,806,800,000 | 2,750,300,000 | 2,245,000,000 | 2,060,900,000 | 2,217,400,000 | 2,189,400,000 | 1,988,400,000 | 2,189,200,000 | 2,254,300,000 | 2,213,400,000 | 2,146,200,000 | 2,190,500,000 | 2,346,300,000 | 2,832,100,000 | 2,360,100,000 | 2,112,100,000 | 2,232,600,000 | 2,220,900,000 | 2,001,100,000 | 2,200,600,000 | 2,276,600,000 | 2,460,300,000 | 2,099,700,000 | 2,625,500,000 | 2,516,800,000 | 2,472,600,000 | 2,060,600,000 | 2,036,300,000 | 2,330,800,000 | 2,110,900,000 | 2,297,600,000 | 2,274,400,000 | 2,816,400,000 | 2,590,400,000 |
total current liabilities | 36,634,000,000 | 35,228,000,000 | 40,140,900,000 | 39,019,900,000 | 30,068,100,000 | 28,376,600,000 | 24,674,100,000 | 27,121,200,000 | 18,598,100,000 | 27,293,200,000 | 21,998,200,000 | 18,915,000,000 | 16,010,000,000 | 17,138,200,000 | 15,652,800,000 | 15,620,600,000 | 13,386,000,000 | 15,052,700,000 | 13,682,000,000 | 15,093,200,000 | 11,714,200,000 | 12,481,600,000 | 11,976,900,000 | 11,988,500,000 | 12,610,200,000 | 11,775,200,000 | 10,828,600,000 | 11,855,400,000 | 11,236,100,000 | 11,888,100,000 | 10,826,700,000 | 13,055,200,000 | 11,547,000,000 | 14,535,900,000 | 12,666,500,000 | 11,294,500,000 | 10,448,000,000 | 10,986,600,000 | 8,272,800,000 | 8,401,000,000 | 7,340,900,000 | 8,229,600,000 | 8,303,300,000 | 8,232,000,000 | 8,342,900,000 | 11,207,500,000 | 7,574,600,000 | 7,417,400,000 | 6,631,700,000 | 8,076,100,000 | 8,408,500,000 | 7,593,600,000 | 6,960,700,000 | 6,609,700,000 |
noncurrent liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term debt | 39,370,000,000 | 40,868,000,000 | 40,873,600,000 | 34,180,100,000 | 34,499,500,000 | 28,527,100,000 | 29,045,400,000 | 23,730,400,000 | 24,559,900,000 | 18,320,800,000 | 17,923,600,000 | 18,158,400,000 | 18,880,500,000 | 14,737,500,000 | 14,143,800,000 | 14,692,000,000 | 15,152,900,000 | 15,346,400,000 | 15,522,400,000 | 14,736,600,000 | 16,199,600,000 | 16,586,600,000 | 16,334,600,000 | 15,064,400,000 | 13,982,300,000 | 13,817,900,000 | 13,662,200,000 | 13,717,600,000 | 13,610,200,000 | 11,639,700,000 | 11,674,700,000 | 9,170,500,000 | 9,393,500,000 | 9,940,500,000 | 9,926,600,000 | 9,867,900,000 | 7,637,500,000 | 8,367,800,000 | 8,707,300,000 | 8,685,500,000 | 7,477,600,000 | 7,972,400,000 | 8,069,600,000 | 7,988,600,000 | 7,415,300,000 | 5,367,700,000 | 5,292,600,000 | 5,301,000,000 | 5,255,300,000 | 4,263,800,000 | 4,290,800,000 | 4,431,600,000 | 5,510,900,000 | 5,500,200,000 |
long-term income taxes payable | 5,289,000,000 | 5,875,000,000 | 6,293,600,000 | 5,684,300,000 | 5,370,500,000 | 4,060,900,000 | 3,878,800,000 | 3,496,600,000 | 4,189,400,000 | 3,849,200,000 | 3,468,300,000 | 3,330,700,000 | 3,842,100,000 | 3,709,600,000 | 3,641,700,000 | 3,557,600,000 | 3,978,100,000 | 3,920,000,000 | 3,768,500,000 | 3,738,000,000 | 3,917,500,000 | 3,837,800,000 | 3,392,700,000 | 3,377,500,000 | 3,621,900,000 | 3,607,200,000 | 3,526,500,000 | 3,485,700,000 | 3,760,400,000 | 3,724,600,000 | 3,740,500,000 | 3,506,600,000 | 3,748,100,000 | 3,776,500,000 | 710,000,000 | 705,000,000 | 697,200,000 | 688,900,000 | 805,600,000 | 805,100,000 | 908,000,000 | 868,900,000 | 910,600,000 | 1,026,800,000 | 954,000,000 | 998,500,000 | 932,800,000 | 940,100,000 | 906,600,000 | 853,500,000 | 1,410,600,000 | 1,363,700,000 | 1,275,100,000 | 1,207,500,000 |
other noncurrent liabilities | 4,085,000,000 | 3,970,000,000 | 3,776,500,000 | 2,344,700,000 | 2,288,400,000 | 2,178,200,000 | 2,239,400,000 | 2,470,700,000 | 2,270,800,000 | 2,240,600,000 | 1,906,100,000 | 1,951,800,000 | 1,822,500,000 | 1,736,700,000 | 1,852,900,000 | 1,783,100,000 | 1,713,900,000 | 1,644,300,000 | 1,748,700,000 | 1,801,900,000 | 1,737,300,000 | 1,707,500,000 | 1,702,600,000 | 1,826,800,000 | 1,873,000,000 | 1,014,300,000 | 1,100,400,000 | 1,142,800,000 | 1,169,800,000 | 2,835,600,000 | 1,547,800,000 | 1,585,600,000 | 1,574,100,000 | 1,546,300,000 | 2,288,600,000 | 2,443,800,000 | 2,282,200,000 | 2,228,200,000 | 2,111,000,000 | 1,907,100,000 | 1,829,300,000 | 1,747,400,000 | 1,422,100,000 | 1,454,100,000 | 1,474,400,000 | 1,653,500,000 | 1,642,200,000 | 1,836,600,000 | 2,061,500,000 | 1,268,200,000 | 1,258,000,000 | 1,295,200,000 | 1,815,000,000 | 1,472,800,000 |
total noncurrent liabilities | 48,744,000,000 | 50,713,000,000 | 50,943,700,000 | 43,553,600,000 | 43,473,900,000 | 36,066,700,000 | 36,612,100,000 | 31,118,100,000 | 32,448,000,000 | 25,849,400,000 | ||||||||||||||||||||||||||||||||||||||||||||
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock | 590,000,000 | 591,400,000 | 592,000,000 | 592,600,000 | 593,900,000 | 594,200,000 | 594,200,000 | 593,600,000 | 593,600,000 | 593,500,000 | 594,100,000 | 594,100,000 | 594,100,000 | 598,200,000 | 598,100,000 | 599,700,000 | 598,100,000 | 598,100,000 | 598,100,000 | 600,400,000 | 603,700,000 | 607,100,000 | 667,100,000 | 673,500,000 | 680,800,000 | 688,500,000 | 688,500,000 | 690,000,000 | 690,400,000 | 690,300,000 | 690,300,000 | 693,000,000 | 693,300,000 | 694,100,000 | 696,600,000 | 699,000,000 | 700,100,000 | 704,700,000 | 704,700,000 | 704,500,000 | 725,800,000 | 725,800,000 | ||||||||||||
additional paid-in capital | 6,921,000,000 | 7,346,000,000 | 7,231,900,000 | 7,089,300,000 | 6,910,000,000 | 7,439,300,000 | 7,339,600,000 | 7,214,200,000 | 7,009,500,000 | 7,250,400,000 | 7,160,000,000 | 6,948,600,000 | 6,793,100,000 | 6,921,400,000 | 6,829,000,000 | 6,746,000,000 | 6,656,300,000 | 6,833,400,000 | 6,758,000,000 | 6,669,200,000 | 6,579,200,000 | 6,778,500,000 | 6,698,800,000 | 6,629,400,000 | 6,556,100,000 | 6,685,300,000 | 6,608,700,000 | 6,534,500,000 | 5,756,600,000 | 6,583,600,000 | 6,522,900,000 | 5,825,700,000 | 5,758,000,000 | 5,817,800,000 | 5,754,700,000 | 5,686,100,000 | 5,617,600,000 | 5,640,600,000 | 5,648,600,000 | 5,587,800,000 | 5,523,000,000 | 5,552,100,000 | 5,441,900,000 | 5,368,500,000 | 5,279,600,000 | 5,292,300,000 | 5,222,000,000 | 5,120,300,000 | 5,034,600,000 | 5,042,300,000 | 4,969,600,000 | 4,902,900,000 | 4,919,900,000 | 4,890,100,000 |
retained earnings | 29,514,000,000 | 24,470,000,000 | 22,252,000,000 | 17,376,200,000 | 15,099,500,000 | 13,545,000,000 | 13,627,200,000 | 13,178,000,000 | 12,553,900,000 | 10,312,300,000 | 10,309,900,000 | 10,368,500,000 | 10,639,300,000 | 10,042,600,000 | 10,006,500,000 | 8,556,000,000 | 9,369,400,000 | 8,958,500,000 | 9,639,400,000 | 8,530,100,000 | 9,181,300,000 | 7,830,200,000 | 7,154,000,000 | 6,617,200,000 | 5,879,400,000 | 4,920,400,000 | 4,981,900,000 | 4,318,100,000 | 4,879,400,000 | 11,395,900,000 | 14,408,700,000 | 14,247,300,000 | 16,608,200,000 | 13,894,100,000 | 16,145,500,000 | 15,590,100,000 | 15,876,700,000 | 16,046,300,000 | 16,601,600,000 | 15,824,100,000 | 16,155,000,000 | 16,011,800,000 | 16,856,700,000 | 16,114,900,000 | 16,706,800,000 | 16,482,700,000 | 17,406,900,000 | 17,204,300,000 | 17,665,300,000 | 17,811,000,000 | 16,608,600,000 | 16,462,400,000 | 17,062,200,000 | 15,736,200,000 |
employee benefit trust | -3,013,000,000 | -3,013,000,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 | -3,013,200,000 |
accumulated other comprehensive loss | -2,833,000,000 | -2,880,000,000 | -3,206,300,000 | -3,716,000,000 | -3,774,600,000 | -4,321,900,000 | -4,274,800,000 | -4,378,500,000 | -4,299,500,000 | -4,327,000,000 | -3,784,900,000 | -3,788,700,000 | -3,777,300,000 | -3,844,600,000 | -4,295,800,000 | -4,287,700,000 | -4,225,300,000 | -4,343,100,000 | -6,172,700,000 | -6,287,100,000 | -6,395,600,000 | -6,496,400,000 | -6,555,100,000 | -6,682,900,000 | -6,885,900,000 | -6,523,600,000 | -5,734,500,000 | -5,600,500,000 | -5,687,500,000 | -5,729,200,000 | -5,439,500,000 | -6,108,700,000 | -5,437,500,000 | -5,718,600,000 | -4,609,400,000 | -4,774,900,000 | -5,064,300,000 | -5,274,000,000 | -4,257,700,000 | -4,371,200,000 | -4,264,700,000 | -4,580,700,000 | -4,667,000,000 | -4,403,200,000 | -4,657,500,000 | -3,991,800,000 | -2,551,600,000 | -1,935,300,000 | -1,957,300,000 | -3,564,100,000 | -3,948,700,000 | -4,014,400,000 | -3,535,900,000 | -3,934,200,000 |
other equity | 19,000,000 | 22,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
total equity | 31,198,000,000 | 26,535,000,000 | 23,850,800,000 | 18,349,100,000 | 15,846,800,000 | 14,271,600,000 | 14,320,700,000 | 13,635,500,000 | 12,897,400,000 | 10,863,700,000 | 11,307,400,000 | 11,149,300,000 | 11,294,900,000 | 10,775,400,000 | 10,165,900,000 | 8,659,200,000 | 9,462,000,000 | 9,154,800,000 | 7,954,100,000 | 6,663,500,000 | 7,099,300,000 | 5,825,200,000 | 4,996,000,000 | 4,272,000,000 | 3,197,200,000 | 2,699,100,000 | 3,462,300,000 | 2,857,300,000 | 2,565,000,000 | 10,909,100,000 | 14,150,900,000 | 11,620,800,000 | 14,587,800,000 | 11,667,900,000 | 14,960,600,000 | 14,169,700,000 | 14,103,700,000 | 14,080,500,000 | 15,615,800,000 | 14,656,200,000 | 15,029,400,000 | 14,590,300,000 | 15,240,900,000 | 14,705,400,000 | 14,946,500,000 | 15,388,100,000 | 17,682,500,000 | 17,994,800,000 | 18,348,700,000 | |||||
total liabilities and equity | 116,576,000,000 | 112,476,000,000 | 114,935,400,000 | 100,922,600,000 | 89,388,800,000 | 78,714,900,000 | 75,606,900,000 | 71,874,800,000 | 63,943,500,000 | 64,006,300,000 | 57,915,500,000 | 54,814,000,000 | 53,163,000,000 | 49,489,800,000 | 47,461,500,000 | 47,063,600,000 | 46,919,300,000 | 48,806,000,000 | 48,187,000,000 | 47,809,000,000 | 46,838,300,000 | 46,633,100,000 | 43,946,000,000 | 41,967,000,000 | 41,102,800,000 | 39,286,100,000 | 37,893,100,000 | 38,666,400,000 | 38,006,800,000 | 43,908,400,000 | 44,625,100,000 | 42,359,200,000 | 44,355,600,000 | 44,981,000,000 | 43,010,400,000 | 40,946,500,000 | 37,624,300,000 | 38,805,900,000 | 37,590,300,000 | 36,475,300,000 | 34,691,800,000 | 35,568,900,000 | 36,304,700,000 | 36,036,600,000 | 35,653,900,000 | 37,178,200,000 | 34,648,800,000 | 35,018,400,000 | 34,756,900,000 | |||||
common stock—no par valueauthorized shares: 3,200.0issued shares: 944.8 | 590,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term investments | 121,600,000 | 170,100,000 | 127,400,000 | 154,800,000 | 149,400,000 | 140,400,000 | 126,100,000 | 109,100,000 | 113,100,000 | 134,600,000 | 123,400,000 | 144,800,000 | 124,700,000 | 113,800,000 | 109,100,000 | 90,100,000 | 37,100,000 | 51,200,000 | 49,000,000 | 24,200,000 | 35,000,000 | 22,800,000 | 78,400,000 | 101,000,000 | 89,200,000 | 77,700,000 | 100,700,000 | 88,200,000 | 76,100,000 | 92,200,000 | 1,705,200,000 | 1,497,900,000 | 3,218,800,000 | 2,364,200,000 | 888,700,000 | 1,456,500,000 | 737,800,000 | 696,800,000 | 687,400,000 | 785,400,000 | 1,080,400,000 | 915,400,000 | 1,075,000,000 | 955,400,000 | 1,644,100,000 | 1,360,800,000 | 1,324,400,000 | 1,010,400,000 | 924,500,000 | 795,800,000 | 1,580,700,000 | 915,700,000 | ||
short-term income taxes payable | 9,444,400,000 | 6,958,000,000 | 6,175,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
eli lilly and company shareholders' equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of common stock in treasury | -62,500,000 | -55,400,000 | -49,500,000 | -49,500,000 | -32,700,000 | -32,700,000 | -32,700,000 | -44,200,000 | -45,000,000 | -45,000,000 | -45,000,000 | -50,500,000 | -50,500,000 | -50,500,000 | -50,500,000 | -52,700,000 | -52,700,000 | -52,700,000 | -52,700,000 | -55,700,000 | -55,700,000 | -55,700,000 | -55,700,000 | -60,800,000 | -60,800,000 | -62,100,000 | -62,100,000 | -69,400,000 | -69,400,000 | -69,400,000 | -69,300,000 | -75,800,000 | -75,800,000 | -75,800,000 | -75,800,000 | -80,500,000 | -80,500,000 | -80,500,000 | -80,500,000 | -90,000,000 | -90,000,000 | -90,000,000 | -90,000,000 | -91,400,000 | -91,400,000 | -91,400,000 | -93,600,000 | -93,600,000 | -93,600,000 | -94,300,000 | -94,300,000 | |||
total eli lilly and company shareholders' equity | 23,793,300,000 | 18,272,900,000 | 15,764,800,000 | 14,192,100,000 | 14,240,000,000 | 13,562,000,000 | 12,812,200,000 | 10,771,900,000 | 11,220,400,000 | 11,063,800,000 | 11,190,400,000 | 10,649,800,000 | 10,070,100,000 | 8,544,700,000 | 9,330,800,000 | 8,979,200,000 | 5,641,600,000 | 2,606,900,000 | 9,828,700,000 | 11,592,200,000 | 14,007,700,000 | 14,571,300,000 | 15,373,200,000 | |||||||||||||||||||||||||||||||
noncontrolling interests | 57,500,000 | 76,200,000 | 82,000,000 | 79,500,000 | 80,700,000 | 73,500,000 | 85,200,000 | 91,800,000 | 87,000,000 | 85,500,000 | 104,500,000 | 125,600,000 | 95,800,000 | 114,500,000 | 131,200,000 | 175,600,000 | 197,100,000 | 219,100,000 | 200,600,000 | 183,600,000 | 169,100,000 | 179,100,000 | 118,400,000 | 92,200,000 | 79,800,000 | 76,800,000 | 84,700,000 | 1,080,400,000 | 1,074,300,000 | 65,600,000 | 60,800,000 | 75,700,000 | 70,300,000 | 68,900,000 | 72,700,000 | 72,800,000 | 26,600,000 | 18,900,000 | 19,500,000 | 19,000,000 | 19,500,000 | 35,100,000 | 26,700,000 | 14,900,000 | 13,200,000 | 11,100,000 | 10,600,000 | 9,000,000 | 9,000,000 | 7,000,000 | -7,600,000 | -2,500,000 | ||
dividends payable | 1,345,200,000 | 1,346,300,000 | 1,170,500,000 | 1,169,200,000 | 1,016,200,000 | 1,017,200,000 | 882,200,000 | 885,500,000 | 770,800,000 | 770,600,000 | 671,500,000 | 593,900,000 | 650,800,000 | 578,200,000 | 590,600,000 | 547,500,000 | 548,100,000 | 537,500,000 | 539,000,000 | 529,200,000 | 530,300,000 | 524,100,000 | 527,000,000 | 543,600,000 | ||||||||||||||||||||||||||||||
accrued retirement benefits | 1,344,500,000 | 1,315,500,000 | 1,300,500,000 | 1,448,500,000 | 1,420,400,000 | 1,427,900,000 | 1,438,800,000 | 1,311,900,000 | 1,308,800,000 | 1,313,000,000 | 1,305,100,000 | 1,832,500,000 | 1,888,600,000 | 1,940,300,000 | 1,954,100,000 | 3,878,800,000 | 3,918,500,000 | 3,969,800,000 | 4,094,500,000 | 3,435,500,000 | 3,398,600,000 | 3,632,000,000 | 3,698,200,000 | 2,414,200,000 | 2,723,400,000 | 2,757,600,000 | 2,911,300,000 | 2,684,500,000 | 3,420,500,000 | 3,505,100,000 | 3,513,900,000 | 2,458,100,000 | 2,465,600,000 | 2,455,700,000 | 2,453,900,000 | 2,077,800,000 | 2,020,400,000 | 2,106,600,000 | 2,160,300,000 | 2,358,200,000 | 2,629,700,000 | 2,520,800,000 | 2,562,900,000 | 1,524,100,000 | 1,528,500,000 | 1,553,100,000 | 2,607,900,000 | 2,621,700,000 | 2,660,400,000 | 2,702,400,000 | 2,714,500,000 | |||
common stock—no par valueauthorized shares: 3,200,000issued shares: 947,903 | 592,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par valueauthorized shares: 3,200,000issued shares: 949,781 | 593,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | 5,247,900,000 | 4,532,400,000 | 3,575,200,000 | 2,954,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes payable | 1,977,500,000 | 1,233,800,000 | 1,528,300,000 | 475,100,000 | 685,600,000 | 126,600,000 | 598,300,000 | 126,900,000 | 203,500,000 | 529,900,000 | 791,600,000 | 495,100,000 | 1,173,500,000 | 1,460,800,000 | 667,400,000 | 160,600,000 | 180,700,000 | 222,900,000 | 491,400,000 | 404,000,000 | 409,200,000 | 464,900,000 | 693,000,000 | 532,900,000 | 414,400,000 | 236,000,000 | 122,000,000 | 119,100,000 | 183,000,000 | 88,000,000 | 114,600,000 | 358,900,000 | 700,000,000 | 93,500,000 | 153,500,000 | 168,600,000 | 102,500,000 | 37,500,000 | 37,300,000 | 352,700,000 | 338,200,000 | 33,500,000 | ||||||||||||
other liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
total other liabilities | 24,609,900,000 | 24,749,700,000 | 25,858,100,000 | 21,576,200,000 | 21,642,800,000 | 22,783,800,000 | 24,071,300,000 | 24,598,500,000 | 26,550,900,000 | 26,052,300,000 | 28,024,800,000 | 28,326,300,000 | 26,973,100,000 | 25,706,500,000 | 25,295,400,000 | 24,811,800,000 | 23,602,200,000 | 23,953,700,000 | 24,205,700,000 | 21,111,200,000 | 19,647,500,000 | 17,683,200,000 | 18,220,800,000 | 18,777,200,000 | 15,383,300,000 | 15,482,300,000 | 13,072,600,000 | 13,738,800,000 | 13,701,700,000 | 13,418,100,000 | 12,321,500,000 | 12,749,000,000 | 12,760,500,000 | 13,099,200,000 | 12,364,500,000 | 10,582,600,000 | 9,391,700,000 | 9,606,200,000 | 9,776,500,000 | 8,993,400,000 | 9,581,100,000 | 9,750,900,000 | 11,303,400,000 | 10,895,000,000 | ||||||||||
deferred tax liabilities | 87,300,000 | 171,900,000 | 862,500,000 | 1,286,100,000 | 1,733,700,000 | 1,632,500,000 | 1,857,300,000 | 2,200,600,000 | 2,099,900,000 | 2,107,700,000 | 2,039,200,000 | 2,186,200,000 | 2,187,500,000 | 2,413,700,000 | 2,380,900,000 | 2,399,500,000 | ||||||||||||||||||||||||||||||||||||||
common stock—no par valueauthorized shares: 3,200,000issued shares: 950,632 | 594,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other | 2,741,900,000 | 2,806,700,000 | 2,697,700,000 | 2,530,600,000 | 3,050,600,000 | 3,296,600,000 | 3,233,700,000 | 2,871,500,000 | 3,209,400,000 | 3,104,500,000 | 2,761,900,000 | 2,538,900,000 | 2,369,600,000 | 2,315,500,000 | 2,227,200,000 | 2,146,500,000 | 1,879,200,000 | 1,688,600,000 | 1,570,000,000 | 1,447,500,000 | 1,063,900,000 | 1,010,300,000 | 821,600,000 | 734,600,000 | 756,500,000 | 789,500,000 | 792,000,000 | 604,400,000 | 762,400,000 | 730,100,000 | 797,000,000 | 811,500,000 | 821,500,000 | 1,085,800,000 | 1,111,800,000 | 853,400,000 | 988,900,000 | 987,900,000 | 790,100,000 | 953,300,000 | ||||||||||||||
common stock—no par value authorized shares: 3,200,000 issued shares: 954,116 | 596,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
eli lilly and company shareholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
total eli lilly and company shareholders’ equity | 7,757,000,000 | 6,444,400,000 | 6,898,700,000 | 4,826,900,000 | 4,092,900,000 | 3,078,800,000 | 3,382,500,000 | 2,780,500,000 | 2,480,300,000 | 13,076,600,000 | 11,555,200,000 | 14,527,000,000 | 14,890,300,000 | 14,100,800,000 | 14,031,000,000 | 15,589,200,000 | 14,637,300,000 | 15,009,900,000 | 15,221,400,000 | 14,670,300,000 | 14,919,800,000 | 17,669,300,000 | 17,983,700,000 | 18,338,100,000 | ||||||||||||||||||||||||||||||
common stock—no par value authorized shares: 3,200,000 issued shares: 957,077 | 598,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating lease assets | 532,100,000 | 535,700,000 | 545,500,000 | 546,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
noncurrent assets of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
noncurrent operating lease liabilities | 486,700,000 | 485,200,000 | 503,300,000 | 508,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
noncurrent liabilities of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value authorized shares: 3,200,000 issued shares: 958,056 | 598,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
sundry | 2,194,200,000 | 2,052,100,000 | 1,963,000,000 | 1,892,400,000 | 2,009,200,000 | 1,776,500,000 | 1,746,800,000 | 2,874,300,000 | 2,197,600,000 | 2,060,500,000 | 2,020,200,000 | 1,913,800,000 | 2,279,300,000 | 2,149,900,000 | 2,244,900,000 | 2,220,500,000 | 2,889,600,000 | 2,701,300,000 | 2,489,400,000 | 2,417,700,000 | 2,338,700,000 | 2,441,000,000 | 2,339,000,000 | 1,320,700,000 | 1,880,100,000 | 2,095,800,000 | 2,387,800,000 | 2,195,000,000 | ||||||||||||||||||||||||||
other assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
total other assets | 14,439,300,000 | 15,125,100,000 | 15,255,700,000 | 19,135,900,000 | 16,952,400,000 | 16,983,500,000 | 16,617,200,000 | 16,222,600,000 | 15,451,900,000 | 15,952,500,000 | 15,431,900,000 | 14,944,100,000 | 14,941,800,000 | 15,662,400,000 | 15,668,000,000 | 15,960,500,000 | 17,034,500,000 | 14,495,000,000 | 13,760,800,000 | 13,746,900,000 | 12,996,000,000 | 12,950,000,000 | 12,350,600,000 | 12,643,200,000 | 11,885,400,000 | |||||||||||||||||||||||||||||
common stock—no par value authorized shares: 3,200,000 issued shares: 1,057,639 | 661,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value authorized shares: 3,200,000 issued shares: 1,100,672 | 687,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
land, buildings, equipment, and construction in progress | 17,730,700,000 | 17,533,000,000 | 17,136,600,000 | 17,237,800,000 | 16,927,600,000 | 16,783,100,000 | 16,611,500,000 | 16,404,200,000 | 16,213,300,000 | 16,081,500,000 | 16,113,600,000 | 15,779,600,000 | ||||||||||||||||||||||||||||||||||||||||||
accumulated depreciation | -9,132,200,000 | -8,950,200,000 | -8,711,100,000 | -8,985,900,000 | -8,861,500,000 | -8,750,000,000 | -8,536,200,000 | -8,381,600,000 | -8,262,600,000 | -8,038,200,000 | -8,012,700,000 | -7,808,900,000 | ||||||||||||||||||||||||||||||||||||||||||
common stock—no par value authorized shares: 3,200,000 issued shares: 1,101,586 | 688,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash | 5,405,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value authorized shares: 3,200,000 issued shares: 1,106,063 | 691,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes | 943,600,000 | 912,800,000 | 1,296,700,000 | 1,466,500,000 | 1,352,500,000 | 1,044,400,000 | 760,400,000 | 841,900,000 | 913,600,000 | 726,600,000 | ||||||||||||||||||||||||||||||||||||||||||||
common stock—no par value authorized shares: 3,200,000 issued shares: 1,111,437 | 694,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of common stock in treasury, 810 shares | -91,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill and other intangibles | 4,750,800,000 | 4,670,100,000 | 4,203,100,000 | 4,455,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
land, buildings, equipment, and construction-in-progress | 15,343,000,000 | 15,037,900,000 | 14,887,600,000 | 14,944,400,000 | 14,705,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
less accumulated depreciation | -7,575,600,000 | -7,401,200,000 | -7,264,200,000 | -7,305,500,000 | -7,085,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity | 16,896,100,000 | 15,236,400,000 | 14,955,600,000 | 16,056,900,000 | 14,307,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and shareholders’ equity | 33,965,600,000 | 33,226,000,000 | 32,300,100,000 | 34,321,000,000 | 31,812,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
goodwill and other intangibles – net | 4,508,500,000 | 4,618,600,000 | 5,031,100,000 | 5,142,800,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | 7,396,000,000 | 6,637,700,000 | 5,582,500,000 | 5,660,500,000 | 2,759,300,000 | 4,409,800,000 | 970,300,000 | 2,967,000,000 | 2,242,900,000 | 2,189,700,000 | -57,400,000 | 1,763,200,000 | 1,344,900,000 | 1,937,700,000 | 1,451,700,000 | 952,500,000 | 1,902,900,000 | 1,726,100,000 | 1,110,100,000 | 1,390,200,000 | 1,355,300,000 | 2,116,800,000 | 1,208,400,000 | 1,412,000,000 | 1,456,500,000 | 1,495,700,000 | 1,253,900,000 | 1,327,200,000 | 4,241,600,000 | 1,125,000,000 | 1,149,500,000 | -259,900,000 | 1,217,400,000 | -1,656,900,000 | 555,600,000 | 1,008,000,000 | -110,800,000 | 771,800,000 | 778,000,000 | 747,700,000 | 440,100,000 | 478,400,000 | 799,700,000 | 600,800,000 | 529,500,000 | 428,500,000 | 500,600,000 | 733,500,000 | 727,900,000 | 1,203,100,000 | 1,206,200,000 | 1,548,000,000 | 1,326,600,000 | 923,600,000 | 1,011,100,000 | 1,236,300,000 |
adjustments to reconcile net income to cash flows from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 509,000,000 | 585,700,000 | 470,000,000 | 478,500,000 | 462,800,000 | 484,800,000 | 466,800,000 | 414,400,000 | 400,600,000 | 387,700,000 | 411,000,000 | 366,300,000 | 362,300,000 | 375,000,000 | 362,900,000 | 348,900,000 | 435,700,000 | 445,700,000 | 382,300,000 | 369,300,000 | 350,300,000 | 367,500,000 | 358,400,000 | 324,400,000 | 273,600,000 | 340,700,000 | 288,000,000 | 247,400,000 | 356,500,000 | 345,500,000 | 415,500,000 | 425,200,000 | 422,800,000 | 411,900,000 | 372,900,000 | 395,600,000 | 386,900,000 | 344,600,000 | 392,800,000 | 373,700,000 | 385,500,000 | 343,400,000 | 358,300,000 | 368,500,000 | 357,500,000 | 339,400,000 | 342,400,000 | 348,400,000 | 348,800,000 | 349,000,000 | 363,900,000 | 381,500,000 | 369,700,000 | 362,000,000 | 385,900,000 | 358,200,000 |
change in deferred income taxes | -1,478,000,000 | -748,100,000 | 501,400,000 | -1,068,700,000 | -391,600,000 | -966,700,000 | -429,800,000 | -1,007,600,000 | -279,000,000 | -506,200,000 | -844,300,000 | -431,100,000 | -559,400,000 | 10,400,000 | -1,070,600,000 | -618,400,000 | -506,600,000 | -92,500,000 | -296,000,000 | -294,700,000 | -119,100,000 | -200,700,000 | 159,700,000 | -104,700,000 | 11,200,000 | 85,800,000 | -12,100,000 | 61,100,000 | -72,400,000 | 165,200,000 | 26,800,000 | 157,500,000 | -22,700,000 | -939,600,000 | -143,400,000 | 166,300,000 | 128,800,000 | 88,700,000 | 182,200,000 | 138,000,000 | 30,600,000 | -77,400,000 | -4,500,000 | -559,400,000 | -107,100,000 | -221,500,000 | 63,900,000 | 27,700,000 | 93,500,000 | 608,700,000 | 249,900,000 | -51,000,000 | 55,500,000 | 18,600,000 | 132,100,000 | 207,500,000 |
stock-based compensation expense | 161,000,000 | 136,100,000 | 151,100,000 | 185,100,000 | 153,700,000 | 141,900,000 | 133,200,000 | 211,100,000 | 159,400,000 | 120,200,000 | 215,600,000 | 161,500,000 | 131,200,000 | 92,900,000 | 85,100,000 | 92,100,000 | 101,000,000 | 75,300,000 | 90,100,000 | 91,900,000 | 85,500,000 | 87,800,000 | 71,700,000 | 76,800,000 | 71,800,000 | 81,600,000 | 75,500,000 | 79,500,000 | 75,800,000 | 72,800,000 | 68,500,000 | 70,200,000 | 68,000,000 | 72,200,000 | 69,900,000 | 69,900,000 | 69,300,000 | 66,800,000 | 61,500,000 | 65,000,000 | 62,000,000 | 58,400,000 | 54,700,000 | 55,800,000 | 48,900,000 | 40,600,000 | 38,500,000 | 38,600,000 | 38,300,000 | 36,300,000 | 33,600,000 | 35,200,000 | 34,500,000 | 37,600,000 | 28,200,000 | 36,500,000 |
acquired in-process research and development | 584,000,000 | 528,800,000 | 655,700,000 | 153,800,000 | 1,571,700,000 | 189,200,000 | 2,826,400,000 | 154,300,000 | 110,500,000 | 622,600,000 | 2,975,100,000 | 97,100,000 | 105,000,000 | 168,900,000 | 19,000,000 | 80,000,000 | 153,000,000 | 376,600,000 | 174,000,000 | 25,000,000 | 299,300,000 | 366,300,000 | 0 | 241,800,000 | 52,300,000 | 0 | 77,700,000 | 25,000,000 | 136,900,000 | 329,400,000 | 30,000,000 | 50,000,000 | 205,000,000 | 0 | 857,600,000 | 199,000,000 | 0 | 80,000,000 | 256,000,000 | |||||||||||||||||
other changes in operating assets and liabilities, net of acquisitions and divestitures | -1,664,000,000 | -3,364,200,000 | -9,800,000 | -1,399,100,000 | -1,751,200,000 | 793,300,000 | -840,200,000 | 164,100,000 | 939,100,000 | -72,100,000 | -45,500,000 | -666,500,000 | 221,200,000 | -102,800,000 | 249,400,000 | 926,500,000 | -1,408,100,000 | -247,300,000 | -802,100,000 | -714,300,000 | 184,100,000 | 29,600,000 | -1,429,500,000 | 26,200,000 | 227,400,000 | -913,700,000 | 473,000,000 | -80,000,000 | -941,300,000 | -226,800,000 | -223,400,000 | -1,048,100,000 | ||||||||||||||||||||||||
other operating activities | -175,000,000 | -61,500,000 | 302,300,000 | 54,400,000 | 324,800,000 | 542,800,000 | -32,100,000 | -31,900,000 | 298,600,000 | 192,300,000 | 485,600,000 | -550,700,000 | 168,300,000 | 30,000,000 | 67,700,000 | 5,100,000 | 21,300,000 | 7,000,000 | 9,200,000 | 41,500,000 | 25,300,000 | -6,100,000 | -82,200,000 | |||||||||||||||||||||||||||||||||
net cash from operating activities | 5,333,000,000 | 3,224,600,000 | 8,835,900,000 | 3,086,900,000 | 1,665,600,000 | 2,473,800,000 | 3,711,900,000 | 1,466,200,000 | 1,166,000,000 | -311,900,000 | 2,189,500,000 | 631,900,000 | 1,730,600,000 | 1,579,700,000 | 2,184,800,000 | 820,700,000 | 2,499,200,000 | 2,156,500,000 | 1,631,300,000 | 1,775,500,000 | 1,697,400,000 | 1,815,200,000 | 1,806,600,000 | 2,495,400,000 | 382,400,000 | 1,963,700,000 | 1,510,100,000 | 1,051,500,000 | 311,300,000 | 1,448,700,000 | 2,121,800,000 | 1,517,500,000 | 436,500,000 | 1,743,500,000 | 1,881,100,000 | 1,651,100,000 | 339,900,000 | 2,116,900,000 | 1,659,200,000 | 1,401,800,000 | -326,900,000 | 804,300,000 | 1,104,700,000 | 948,600,000 | -84,800,000 | 1,349,600,000 | 1,691,300,000 | 1,053,900,000 | 272,300,000 | 1,991,600,000 | 1,637,200,000 | 379,400,000 | 1,544,300,000 | 1,306,000,000 | 852,500,000 | 2,073,400,000 |
capital expenditures | -2,326,000,000 | -2,546,700,000 | -2,087,700,000 | -1,697,100,000 | -1,509,500,000 | -1,496,000,000 | -1,350,700,000 | -1,224,800,000 | -986,300,000 | -1,070,600,000 | -970,300,000 | -738,200,000 | -668,500,000 | 0 | -617,200,000 | -371,000,000 | -365,400,000 | 0 | -336,800,000 | -381,300,000 | -300,300,000 | 0 | -393,100,000 | -281,800,000 | -258,300,000 | 0 | -263,400,000 | -240,300,000 | -203,700,000 | 0 | -269,800,000 | -310,000,000 | -236,500,000 | 0 | -242,700,000 | -221,600,000 | -169,000,000 | 0 | -227,500,000 | -245,400,000 | -154,300,000 | 0 | -273,500,000 | -223,900,000 | -188,600,000 | 0 | -296,900,000 | -254,900,000 | -202,000,000 | -253,800,000 | -136,400,000 | -157,900,000 | -182,000,000 | -179,500,000 | -130,700,000 | -175,700,000 |
free cash flows | 3,007,000,000 | 677,900,000 | 6,748,200,000 | 1,389,800,000 | 156,100,000 | 977,800,000 | 2,361,200,000 | 241,400,000 | 179,700,000 | -1,382,500,000 | 1,219,200,000 | -106,300,000 | 1,062,100,000 | 1,579,700,000 | 1,567,600,000 | 449,700,000 | 2,133,800,000 | 2,156,500,000 | 1,294,500,000 | 1,394,200,000 | 1,397,100,000 | 1,815,200,000 | 1,413,500,000 | 2,213,600,000 | 124,100,000 | 1,963,700,000 | 1,246,700,000 | 811,200,000 | 107,600,000 | 1,448,700,000 | 1,852,000,000 | 1,207,500,000 | 200,000,000 | 1,743,500,000 | 1,638,400,000 | 1,429,500,000 | 170,900,000 | 2,116,900,000 | 1,431,700,000 | 1,156,400,000 | -481,200,000 | 804,300,000 | 831,200,000 | 724,700,000 | -273,400,000 | 1,349,600,000 | 1,394,400,000 | 799,000,000 | 70,300,000 | 1,737,800,000 | 1,500,800,000 | 221,500,000 | 1,362,300,000 | 1,126,500,000 | 721,800,000 | 1,897,700,000 |
cash flows from investing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment | -2,326,000,000 | -2,546,700,000 | -2,087,700,000 | -1,697,100,000 | -1,509,500,000 | -1,496,000,000 | -1,350,700,000 | -1,224,800,000 | -986,300,000 | -1,070,600,000 | -970,300,000 | -738,200,000 | -668,500,000 | |||||||||||||||||||||||||||||||||||||||||||
purchases of noncurrent investments | -297,000,000 | -127,000,000 | -150,100,000 | -171,200,000 | -196,700,000 | -152,200,000 | -275,000,000 | -133,000,000 | -117,100,000 | -256,000,000 | -131,400,000 | -197,400,000 | -146,000,000 | -126,100,000 | -222,700,000 | -134,700,000 | -116,700,000 | -219,800,000 | -207,000,000 | -211,600,000 | -291,500,000 | -135,000,000 | -68,900,000 | -71,800,000 | -83,000,000 | -50,800,000 | -50,100,000 | -86,000,000 | -60,600,000 | -118,200,000 | -43,200,000 | -114,900,000 | -561,600,000 | -872,000,000 | -1,380,800,000 | -1,412,900,000 | -945,900,000 | -705,300,000 | -1,371,500,000 | -1,552,500,000 | -716,700,000 | -553,100,000 | -840,600,000 | -908,400,000 | -924,400,000 | -1,166,000,000 | -3,042,000,000 | -2,824,500,000 | -2,770,200,000 | -3,763,400,000 | -4,614,700,000 | -1,861,400,000 | -2,030,200,000 | -1,320,500,000 | -2,156,100,000 | -1,023,200,000 |
purchases of in-process research and development | -204,000,000 | -423,700,000 | -720,500,000 | -106,800,000 | -1,757,000,000 | -251,200,000 | -2,820,100,000 | -178,000,000 | -96,500,000 | -580,500,000 | -3,030,900,000 | -98,100,000 | -235,000,000 | -54,900,000 | -3,000,000 | -80,000,000 | -491,800,000 | -102,800,000 | -118,800,000 | -150,000,000 | -191,800,000 | -364,800,000 | -22,000,000 | -241,400,000 | -13,000,000 | 0 | ||||||||||||||||||||||||||||||
cash paid for acquisitions, net of cash acquired | -1,058,000,000 | -111,600,000 | 0 | 0 | 0 | 0 | 0 | -747,400,000 | 0 | 0 | 0 | -849,300,000 | 0 | 0 | 0 | -6,917,700,000 | 0 | 0 | 0 | -882,100,000 | 0 | 0 | 4,700,000 | -11,100,000 | 0 | -5,276,700,000 | 0 | 0 | 0 | -3,900,000 | -195,400,000 | |||||||||||||||||||||||||
other investing activities | -31,000,000 | 56,800,000 | -31,000,000 | -64,100,000 | 39,300,000 | -158,800,000 | -169,800,000 | 95,600,000 | -65,200,000 | -22,800,000 | -666,200,000 | 456,800,000 | 40,300,000 | 61,900,000 | -157,000,000 | 22,100,000 | -133,400,000 | 27,000,000 | -53,200,000 | 72,400,000 | -21,900,000 | 86,500,000 | 12,200,000 | -47,300,000 | 51,400,000 | 232,000,000 | -141,500,000 | 46,400,000 | -385,600,000 | -2,500,000 | -143,500,000 | -24,100,000 | -21,200,000 | -37,800,000 | -61,100,000 | -109,100,000 | -7,800,000 | -55,000,000 | -43,300,000 | 4,700,000 | -36,500,000 | -30,900,000 | -41,000,000 | -59,000,000 | -2,700,000 | 25,900,000 | -18,900,000 | -19,600,000 | -11,900,000 | -35,800,000 | -37,300,000 | -18,400,000 | 49,700,000 | -60,600,000 | -50,900,000 | -1,900,000 |
net cash from investing activities | -3,916,000,000 | -2,802,200,000 | -2,982,600,000 | -1,834,900,000 | -3,352,300,000 | -1,920,500,000 | -4,004,700,000 | -2,198,700,000 | -1,177,600,000 | -2,924,300,000 | -3,080,500,000 | -459,100,000 | -688,800,000 | -860,500,000 | -923,400,000 | -463,900,000 | -1,013,800,000 | -379,000,000 | -616,500,000 | -483,300,000 | -1,283,500,000 | -674,100,000 | -313,500,000 | -210,400,000 | -1,060,900,000 | -41,400,000 | -423,800,000 | 61,000,000 | -7,678,700,000 | -659,000,000 | -398,100,000 | 3,133,400,000 | -170,300,000 | 1,652,900,000 | -1,758,000,000 | -2,248,900,000 | -1,429,600,000 | -1,178,100,000 | -794,700,000 | -1,020,900,000 | -145,400,000 | 253,700,000 | -570,100,000 | 182,400,000 | 160,800,000 | -2,178,900,000 | -1,649,700,000 | -468,900,000 | 388,400,000 | -943,800,000 | -1,251,700,000 | 1,355,100,000 | -132,700,000 | -385,300,000 | -652,300,000 | -1,008,300,000 |
cash flows from financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
dividends paid | -1,548,000,000 | -1,345,500,000 | -1,345,200,000 | -1,347,000,000 | -1,346,300,000 | -1,168,300,000 | -1,170,500,000 | -1,172,400,000 | -1,169,200,000 | -1,018,100,000 | -1,016,200,000 | -1,017,800,000 | -1,017,200,000 | -884,400,000 | -882,200,000 | -883,700,000 | -885,500,000 | -773,300,000 | -770,400,000 | -768,300,000 | -774,800,000 | -670,000,000 | -671,600,000 | -674,200,000 | -671,300,000 | -587,200,000 | -587,400,000 | -598,000,000 | -637,200,000 | -572,600,000 | -572,600,000 | -579,300,000 | -587,300,000 | -548,300,000 | -547,700,000 | -548,700,000 | -547,400,000 | -541,100,000 | -537,900,000 | -541,200,000 | -538,300,000 | -533,300,000 | -526,300,000 | -539,800,000 | -527,900,000 | -525,200,000 | -525,000,000 | -526,900,000 | -524,100,000 | -527,700,000 | -533,000,000 | -531,100,000 | -544,200,000 | -550,400,000 | -544,600,000 | -540,900,000 |
net change in short-term borrowings | 1,775,000,000 | -400,000 | -4,091,700,000 | 1,602,800,000 | -1,848,700,000 | 3,042,300,000 | -3,089,400,000 | 3,400,100,000 | -5,204,800,000 | 4,594,400,000 | 1,595,000,000 | 0 | -1,498,000,000 | -243,300,000 | -375,900,000 | 1,617,500,000 | 499,700,000 | -2,500,000 | -197,800,000 | 200,000,000 | -3,700,000 | -579,900,000 | -678,900,000 | -1,984,100,000 | 1,748,700,000 | -63,500,000 | -505,400,000 | -286,100,000 | 1,850,400,000 | 99,200,000 | -2,048,400,000 | 953,800,000 | -1,202,500,000 | 170,700,000 | 1,101,100,000 | -371,800,000 | 497,500,000 | 1,294,900,000 | -300,000 | -500,000 | -2,300,000 | -12,400,000 | 99,900,000 | |||||||||||||
proceeds from issuance of long-term debt | -200,000 | 6,706,200,000 | 0 | 6,461,000,000 | 0 | 4,964,600,000 | 0 | 6,452,500,000 | 0 | 0 | 0 | 3,958,500,000 | 0 | 0 | 1,073,700,000 | 2,108,100,000 | 0 | 0 | 4,448,300,000 | 0 | 0 | 0 | 0 | 0 | 100,000 | 0 | 2,272,600,000 | 2,182,000,000 | 0 | 0 | 0 | 992,900,000 | ||||||||||||||||||||||||
repayments of long-term debt | -750,000,000 | 100,000 | 0 | 0 | 0 | 0 | 0 | -849,900,000 | -710,100,000 | -100,000 | -200,000 | 0 | 0 | -276,300,000 | -2,266,100,000 | -100,000 | -200,000 | -600,000,000 | -7,600,000 | 0 | -201,200,000 | -800,300,000 | 0 | -100,000 | -300,000 | -630,200,000 | ||||||||||||||||||||||||||||||
purchases of common stock | -2,356,000,000 | -1,507,700,000 | -708,100,000 | -692,200,000 | -1,200,000,000 | -2,053,900,000 | 0 | 0 | 0 | -750,000,000 | 0 | 0 | 0 | -1,500,000,000 | -750,000,000 | 0 | 0 | 0 | 0 | -500,000,000 | -300,000,000 | -600,000,000 | 0 | -3,500,000,000 | -1,100,000,000 | -1,000,000,000 | -950,700,000 | -1,100,000,000 | -99,900,000 | 0 | -300,000,000 | 0 | 0 | -300,100,000 | -252,900,000 | -61,100,000 | -124,900,000 | -310,600,000 | -300,000,000 | -300,000,000 | -145,000,000 | -55,000,000 | 0 | 0 | -1,198,100,000 | |||||||||||
other financing activities | -591,000,000 | -25,100,000 | -30,200,000 | -30,400,000 | -686,300,000 | -45,500,000 | -47,300,000 | -8,000,000 | -389,800,000 | -31,600,000 | -6,800,000 | -15,600,000 | -281,000,000 | -13,700,000 | -5,200,000 | -7,600,000 | -282,400,000 | -600,000 | -500,000 | -14,900,000 | -279,900,000 | -41,400,000 | -2,300,000 | -3,500,000 | -194,400,000 | -4,900,000 | 0 | -1,500,000 | -193,700,000 | -58,700,000 | -83,700,000 | -54,000,000 | -176,400,000 | -64,800,000 | -52,600,000 | -51,400,000 | -195,600,000 | -179,000,000 | -59,300,000 | -85,600,000 | 23,100,000 | 111,500,000 | -5,000,000 | -12,700,000 | 45,400,000 | 78,400,000 | 117,000,000 | -1,100,000 | -6,900,000 | 100,000 | ||||||
net cash from financing activities | -3,470,000,000 | -2,878,800,000 | 531,000,000 | -1,244,900,000 | 1,379,700,000 | -225,400,000 | 211,300,000 | 1,555,500,000 | -311,300,000 | 3,544,700,000 | 572,000,000 | -1,033,400,000 | 412,300,000 | -1,141,400,000 | -1,263,300,000 | -123,700,000 | -2,878,300,000 | -1,526,500,000 | -463,200,000 | -1,083,200,000 | -1,058,400,000 | -1,291,500,000 | -279,100,000 | -1,673,200,000 | 106,700,000 | -1,113,600,000 | -1,692,900,000 | -885,800,000 | 1,367,800,000 | -1,639,700,000 | 432,700,000 | -831,400,000 | -3,866,500,000 | -542,300,000 | 500,700,000 | 1,059,900,000 | -875,700,000 | 274,800,000 | -597,600,000 | 579,400,000 | -816,400,000 | -679,600,000 | -595,200,000 | -943,200,000 | -701,200,000 | 1,628,400,000 | -405,900,000 | -702,500,000 | -595,100,000 | -529,000,000 | -533,800,000 | -1,730,100,000 | -544,700,000 | -552,700,000 | -2,057,000,000 | -440,900,000 |
effect of exchange rate changes on cash and cash equivalents | 67,000,000 | -67,100,000 | 31,700,000 | 275,500,000 | 131,900,000 | -428,500,000 | 226,900,000 | -59,600,000 | -35,500,000 | 129,300,000 | 5,300,000 | 9,200,000 | 24,800,000 | -128,200,000 | -3,600,000 | -69,400,000 | 33,600,000 | -220,700,000 | 16,600,000 | 8,600,000 | -10,200,000 | 212,200,000 | 16,200,000 | 54,300,000 | -66,700,000 | -35,000,000 | -119,800,000 | 27,100,000 | 37,800,000 | -111,800,000 | -13,700,000 | -86,500,000 | 148,400,000 | -42,200,000 | 30,600,000 | -9,100,000 | 200,000 | -120,500,000 | -15,900,000 | -29,900,000 | -70,100,000 | 49,200,000 | -16,100,000 | 62,900,000 | -181,600,000 | -93,300,000 | -235,600,000 | -4,800,000 | -7,800,000 | 63,600,000 | -1,800,000 | -86,600,000 | 106,500,000 | -144,400,000 | 56,500,000 | -140,000,000 |
net decrease in cash and cash equivalents | -1,986,000,000 | -175,100,000 | -5,500,000 | 163,700,000 | -1,359,300,000 | -654,700,000 | -638,500,000 | -5,961,800,000 | -3,451,900,000 | 654,400,000 | 453,000,000 | -1,965,200,000 | 251,000,000 | 930,400,000 | -1,358,800,000 | -76,700,000 | -150,100,000 | -82,200,000 | ||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at january 1 | 7,268,000,000 | 0 | 0 | 3,268,400,000 | 0 | 0 | 2,818,600,000 | 0 | 0 | 2,067,000,000 | 0 | 0 | 3,818,500,000 | 0 | 0 | 3,657,100,000 | 0 | 0 | 2,337,500,000 | 0 | 0 | 7,998,200,000 | 0 | 0 | 6,536,200,000 | 0 | 0 | 4,582,100,000 | 0 | 0 | 3,666,400,000 | 0 | 0 | 3,871,600,000 | 0 | 0 | 3,830,200,000 | 0 | 0 | 4,018,800,000 | 0 | 0 | 5,922,500,000 | 0 | ||||||||||||
cash and cash equivalents at march 31 | 5,282,000,000 | 3,093,300,000 | 2,460,200,000 | 3,545,900,000 | 2,459,200,000 | 3,002,400,000 | 1,699,000,000 | 2,036,400,000 | 3,084,300,000 | 2,616,900,000 | 2,307,600,000 | 3,064,800,000 | 3,888,000,000 | 3,936,600,000 | 4,122,200,000 | |||||||||||||||||||||||||||||||||||||||||
gains on sale of product rights | -123,100,000 | -25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
other changes in operating assets and liabilities, net of acquisitions and divestitures: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivables—decrease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
inventories—decrease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other assets—decrease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable and other liabilities—increase | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of and distributions from noncurrent investments | 132,000,000 | 556,100,000 | 204,300,000 | 71,600,000 | 55,600,000 | 67,900,000 | 179,600,000 | 70,500,000 | 31,900,000 | 87,800,000 | 106,500,000 | 281,900,000 | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of product rights | 70,400,000 | 0 | 0 | 0 | 0 | 410,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | -2,523,500,000 | 6,416,000,000 | -100,600,000 | 145,400,000 | 763,400,000 | -358,400,000 | 437,800,000 | -313,700,000 | -851,400,000 | 1,478,900,000 | 30,300,000 | 568,200,000 | 61,800,000 | 1,230,200,000 | 773,700,000 | -726,400,000 | -961,800,000 | 2,142,700,000 | -806,800,000 | 705,800,000 | 57,800,000 | 973,400,000 | 223,600,000 | -1,800,300,000 | 484,200,000 | |||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other changes in operating assets and liabilities, net of acquisitions | 1,208,200,000 | 293,900,000 | -662,100,000 | -1,270,000,000 | 593,300,000 | -123,500,000 | -995,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at september 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net investment losses | -113,800,000 | 149,100,000 | -112,400,000 | 158,000,000 | -15,800,000 | -121,000,000 | 64,500,000 | 65,800,000 | 14,200,000 | -256,400,000 | 130,800,000 | 119,500,000 | 426,100,000 | |||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at june 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
investment losses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales and maturities of short-term investments | 41,600,000 | 31,900,000 | 34,000,000 | 41,400,000 | 37,000,000 | 45,600,000 | 48,100,000 | 61,500,000 | 38,300,000 | 25,500,000 | 30,900,000 | 26,700,000 | 800,000 | 25,300,000 | 17,300,000 | 4,000,000 | 10,900,000 | 7,600,000 | 74,400,000 | 36,800,000 | 20,300,000 | 26,900,000 | 53,500,000 | 35,900,000 | 17,000,000 | 38,800,000 | 2,046,000,000 | 450,700,000 | 2,532,300,000 | 642,600,000 | 509,200,000 | 1,168,400,000 | 396,100,000 | 320,500,000 | 403,800,000 | 521,600,000 | 576,000,000 | 300,500,000 | 778,100,000 | 507,200,000 | 1,392,500,000 | 771,900,000 | 722,800,000 | 1,166,900,000 | 396,200,000 | 374,400,000 | 1,607,500,000 | |||||||||
purchases of short-term investments | -29,900,000 | -19,800,000 | -24,400,000 | -24,400,000 | -19,000,000 | -19,400,000 | -36,800,000 | -23,000,000 | -42,400,000 | -32,100,000 | -18,300,000 | -14,600,000 | -55,600,000 | -1,300,000 | -7,200,000 | -19,400,000 | 0 | -8,600,000 | 0 | -400,000 | -33,700,000 | 0 | 0 | 0 | -112,200,000 | -415,900,000 | -1,090,300,000 | -1,594,100,000 | -289,400,000 | -901,700,000 | -160,400,000 | -166,900,000 | -98,400,000 | -78,000,000 | -175,700,000 | -422,700,000 | -165,800,000 | -236,000,000 | -597,300,000 | -401,700,000 | -402,800,000 | -263,000,000 | -202,500,000 | -313,100,000 | ||||||||||||
debt extinguishment loss | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
other assets—decrease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other non-cash operating activities | 87,200,000 | 266,800,000 | -81,800,000 | 32,600,000 | 6,700,000 | 185,100,000 | 188,500,000 | 131,100,000 | 121,700,000 | -96,500,000 | 383,600,000 | -74,900,000 | 193,200,000 | 74,400,000 | 113,400,000 | -32,300,000 | 151,300,000 | 137,600,000 | 162,100,000 | 21,000,000 | 75,800,000 | 227,800,000 | 134,800,000 | 3,100,000 | 83,300,000 | 60,600,000 | 51,200,000 | 184,400,000 | 227,100,000 | -129,700,000 | -11,400,000 | -49,600,000 | ||||||||||||||||||||||||
income taxes payable—increase | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of noncurrent investments | 90,600,000 | 83,100,000 | 87,100,000 | 81,400,000 | 262,800,000 | 75,300,000 | 177,100,000 | 284,800,000 | 183,000,000 | 162,100,000 | 357,500,000 | 54,500,000 | 111,400,000 | 82,000,000 | 332,800,000 | 83,600,000 | 64,800,000 | 49,600,000 | 3,084,600,000 | 310,500,000 | 899,100,000 | 579,300,000 | 579,600,000 | 528,000,000 | 479,200,000 | 687,500,000 | 580,400,000 | 338,900,000 | 796,600,000 | 521,300,000 | 1,154,300,000 | 596,200,000 | 3,653,900,000 | 1,815,400,000 | ||||||||||||||||||||||
net purchases of property and equipment | -617,200,000 | -371,000,000 | -365,400,000 | -336,800,000 | -381,300,000 | -300,300,000 | -393,100,000 | -281,800,000 | -258,300,000 | -263,400,000 | -240,300,000 | -203,700,000 | -269,800,000 | -310,000,000 | -236,500,000 | -242,700,000 | -221,600,000 | -169,000,000 | -227,500,000 | -245,400,000 | -154,300,000 | -273,500,000 | -223,900,000 | -188,600,000 | -296,900,000 | -254,900,000 | -202,000,000 | -253,800,000 | -136,400,000 | -157,900,000 | -182,000,000 | -179,500,000 | -130,700,000 | -175,700,000 | ||||||||||||||||||||||
gain related to disposition of elanco | 0 | 0 | 0 | -3,680,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of antibiotic business in china | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net investment gains | 93,100,000 | 247,000,000 | -215,900,000 | -302,200,000 | -529,000,000 | -144,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash distributed to elanco upon disposition | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash received for sale of antibiotic business in china | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net proceeds from elanco initial public offering | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net incometo cash flows from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of in-process research and development | -45,000,000 | -196,900,000 | -30,000,000 | -205,000,000 | 0 | -831,800,000 | -50,000,000 | -136,000,000 | -200,000,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from disposals of property and equipment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
disposals of property and equipment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash released for pending acquisition | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net proceeds from (payments for) terminations of interest rate swaps | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash released | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of product rights | -100,000 | -236,900,000 | -46,300,000 | -25,000,000 | -172,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
net payments for terminations of interest rate swaps | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash released for acquisition | 0 | 0 | 5,405,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
repayment of long-term debt | -100,000 | -1,400,000 | -1,947,700,000 | -1,500,000 | -500,000 | -31,800,000 | -1,002,000,000 | -1,300,000 | -800,000 | -900,000 | 0 | 0 | -1,500,000,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||
net change in short term borrowings | -1,100,000 | -1,400,000 | -590,700,000 | -2,088,600,000 | 302,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
income related to termination of the exenatide collaboration with amylin pharmaceuticals, inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net proceeds (payments) for terminations of interest rate swaps | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments for terminations of interest rate swaps | -206,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net incometo cash flows from operating activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net realized investment gains | -41,700,000 | -71,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment charges, indefinite lived intangibles | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development, net of tax | 68,400,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
income related to termination of the exenatide collaboration with amylin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from terminations of interest rate swaps | 88,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities, net of acquisitions: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivables—increase | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
inventories—increase | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other assets—increase | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash restricted for pending acquisition | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from prepayment of revenue-sharing obligation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income related to termination of the exenatide collaboration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales and maturities of noncurrent investments | 2,633,400,000 | 3,019,700,000 | 3,364,800,000 | 2,098,400,000 | 1,106,100,000 | 1,028,100,000 | 1,423,200,000 | 647,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
net change in loan to collaboration partner | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income related to transfer of exenatide rights | 0 | -495,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
income related to prepayment of revenue-sharing obligation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other changes in operating assets and liabilities | 488,300,000 | -61,100,000 | -698,700,000 | 166,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
net change in short-term investments | -351,400,000 | 151,100,000 | 457,600,000 | 26,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at sept 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loan to collaboration partner | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid for acquisition, net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net marketing investigation charges paid | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid for acquisition |